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ABSTRACT 
The process of atherosclerosis is multifactorial, and endothelial dysfunction is considered to 
precede atherosclerosis. Angiotensin (Ang) II, the main effector of renin-angiotensin-
aldosterone system (RAAS), is implicated in hypertension and has been shown to promote 
atherosclerosis.  
Familial combined hyperlipidaemia (FCHL) and familial hypercholesterolemia (FH) have 
been identified as risk factors for increased risk of cardiovascular heart disease and premature 
death. FCHL has a different phenotype compared to FH, but both lipid disorders are 
accompanied by subclinical atherosclerosis and endothelial dysfunction. We speculated that 
patients with hypertension and hyperlipidaemia were more sensitive to the potential 
proinflammatory and procoagulatory effects of Ang II than healthy individuals. The present 
research program was set up to investigate the extent to which the RAAS affects the 
inflammatory and thrombotic properties of individuals with hypertension and 
hyperlipidaemia. 
In Paper I we examined the impact of treatment with the ACE inhibitor ramipril on 
coagulation in patients with mild-to-moderate hypertension. We observed that ramipril 
attenuates thrombin generation in essential hypertension by reducing thrombin-antithrombin 
complex, and tended to reduce fibrinogen levels. 
In Paper II we wanted to clarify the impact of antihypertensive treatment per se. Therefore, 
we examined the effects of long-term treatment of ramipril compared to the alpha 1-
adrenoceptor blocker doxazosin on inflammation and haemostasis in patients with mild-to-
moderate hypertension. We found that antihypertensive treatment seems to exert a minor 
impact on systemic inflammation. Treatment with ramipril, but not doxazosin, appeared to 
reduce thrombin generation. This extended our previous findings in paper I suggesting that 
treatment with ramipril reduces thrombin generation in addition to the effects on blood 
pressure reduction alone. Drugs blocking the renin-angiotensin-aldosterone system may 
reduce atherothrombotic complications beyond their effects of lowering blood pressure. We 
also observed a decrease in t-PA antigen and a tendency to decreased PAI-1 activity in the 
doxazosin treated group, which would implicate beneficial effects by treatment with 
doxazosin in hypertensive patients regarding fibrinolysis. This may be of benefit in the 
treatment of patients with hypofibrinolysis, such as patients with FCHL.  
In Paper III we examined how an intravenous infusion of Ang II affected inflammation and 
haemostasis in patients with FCHL and healthy control subjects. In Paper IV we 
characterized the studied the patients with FCHL, in paper III, with respect to insulin 
resistance and in more detail regarding fibrinolysis. We also performed placebo experiments 
to make it possible to assess the influence of diurnal variations and to verify the stability of 
the experimental design. We found that FCHL had an increased systolic blood pressure 
response during infusion of Ang II compared to controls, indicating an increased vascular 
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resistance and in more detail regarding fibrinolysis. We also performed placebo experiments 
to make it possible to assess the influence of diurnal variations and to verify the stability of 
the experimental design. We found that FCHL had an increased systolic blood pressure 
response during infusion of Ang II compared to controls, indicating an increased vascular 
responsiveness in FCHL. Patients with FCHL exhibited a low-grade chronic inflammation, 
an impaired fibrinolysis, while the coagulation system seemed intact. FCHL shared several 
characteristics with the metabolic syndrome, including high triglyceride and low HDL 
cholesterol levels, insulin resistance and high body mass index. An infusion of Ang II 
increased systemic inflammation in a similar way in FCHL and controls. Ang II did not have 
any impact on thrombin generation, in either FCHL or controls. Ang II did not affect 
fibrinolysis in FCHL, whereas fibrinolysis was enhanced in healthy controls. The different 
responses to Ang II stimulation probably involved t-PA activity but not PAI-1 activity, and 
this suggests that patients with FCHL were incapable of increasing fibrinolysis in response to 
Ang II. We could not observe any short-term effects on PAI-1 activity, in either FCHL or 
controls. Our findings suggested that patients with FCHL had a low-grade chronic 
inflammation, impaired fibrinolysis and insulin resistance, contributing to the risk of 
cardiovascular heart disease and premature death in FCHL. We also suggested that Ang II 
acted as a proinflammatory and enhanced fibrinolysis, without impact on thrombin 
generation. However, taking the possible effects of diurnal variations of our coagulation 
markers, not taken into account in paper III, and analysing the impact of Ang II during the 
ongoing infusion time, post hoc analyses showed that thrombin generation instead increased, 
similarly in FCHL and controls. Hence, our new conclusion became that Ang II acts as a 
prothrombotic agent. 
In Paper V we examined how an intravenous infusion of Ang II affected inflammation and 
haemostasis in patients with FH and healthy controls. We also performed placebo 
experiments to make it possible to assess the influence of diurnal variations and to verify the 
stability of the experimental design. We found that patients with FH had higher systolic blood 
pressure than controls at baseline, whereas blood pressure responses were equal in FH and 
controls. FH showed an intact fibrinolysis and an increased thrombin generation potential 
compared to controls, but did not show any convincing signs of an on-going low-grade 
inflammation. A systemic infusion of Ang II caused an increase in systemic inflammation, 
fibrinolysis and possibly also thrombin generation similar in FH and control subjects. During 
Ang II infusion FH exhibited possible signs of an activated anticoagulant system. Our 
findings suggested that patients with FH had an affected coagulation system, rather than 
altered fibrinolysis or inflammation, contributing to the increased risk of cardiovascular heart 
disease and premature death in FH. 
Thus, blocking the renin-angiotensin-aldosterone system by an ACE inhibitor may prevent 
atherothrombotic complications in hypertensive patients beyond the effects on BP by 
reducing thrombin formation. Different mechanisms may contribute to the increased 
incidence of cardiovascular complications in patients with FCHL and FH. A beneficial effect 
of ACE inhibition in patients with FCHL might be to attenuate inflammation in combination 
with its documented positive influence on insulin resistance, while in patients with FH, may 
benefit be obtained mainly by reduced thrombin generation. 
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1  INTRODUCTION 
1.1 GENERAL BACKGROUND 
The most common cause of death in economically developed countries is cardiovascular 
disease (CVD). During the period 1990 to 2010, deaths from CVD increased from 26% to 
30% of all deaths globally. Death rate caused by CVD is expected to decrease to 24% of all 
deaths in 2030, but will still retain its leading position due to an increasing prevalence in 
developing countries (1). The expected decline globally is thought to be due to a dramatic 
shift in deaths from infectious diseases and malnutrition, with very short life expectancy, 
compared to CVD and cancer. Given the high mortality and morbidity burden in CVD, it is 
of great importance for societies and their health care systems to improve strategies to 
decrease the incidence of CVD in the future (2).  
A well-known cause of death within CVD is coronary heart disease (CHD), and traditional 
risk factors for this disease are hypertension, hypercholesterolemia, diabetes mellitus, obesity, 
tobacco smoking, age, male sex and family history. In the EUROASPIRE III trial (figure 1), 
almost 9000 participants with CHD in 22 European countries were included. The study 
showed that more than 50% of the patients had hypertension or hypercholesterolemia and 
35% had diabetes mellitus or were obese (3). 
 
Figure 1. The EUROASPIRE III survey. The bars show prevalence of cardiovascular 
disease risk factors in subjects with established coronary heart disease (n = 8966). 
Hypertension was characterized as a blood pressure above 140/90 mmHg. High 
cholesterol levels were characterized as total cholesterol above 4.5 mmol/L and obesity 
was characterized as a body mass index above 30 kg/m2. HTN, hypertension. Figure 
modified from Volpe M, 2012 (4). 
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The INTERHEART study (5) studied incidence of acute myocardial infarction globally. 
This large-scale study enrolled around 15 000 cases and 15 000 controls. The association of 
nine modifiable risk factors to acute myocardial infarction and a risk referred to as the 
population attributable risk were calculated. The study showed that the incidence of an acute 
myocardial infarction was in more than 90% of the cases associated with the nine measured 
risk factors. The most important risk factor turned out to be abnormal lipids, apolipoprotein 
(Apo) B/ApoA1 ratio, in all geographic regions. Five of the traditionally most common and 
well-described risk factors, hyperlipidaemia, hypertension, tobacco smoking, diabetes 
mellitus and obesity, accounted for around 80% of the population attributable risk. 
Several additional risk factors for CVD have been recognized: hypercoagulability, impaired 
fibrinolysis, hyperinsulinemia, physical inactivity, impaired high-density lipoprotein (HDL) 
cholesterol and psychosocial factors. Most of the risk factors are related to lifestyle and 
metabolic disorders, and often several of the risk factors are present in a cluster. The most 
common condition with several risk factors is the metabolic syndrome. Varying definitions 
are given by different organizations, but the most common risk factors referred to include 
hypertension, dyslipidaemia, insulin resistance and abdominal obesity, culminating in an 
elevated risk of CVD and type 2 diabetes mellitus (6). 
Angiotensin (Ang) II has an important role for inflammation in the vessels. During the past 
decades Ang II has been shown to initiate and accelerate hypertension, endothelial 
dysfunction (ED) and atherosclerosis (7). Conversely, inhibition of the renin-angiotensin-
aldosterone system (RAAS) reduces atherosclerosis in animal models (8), and death from 
CVD in humans (9).  
Ang II may have an impact on thrombosis. The extrinsic coagulation pathway is of great 
importance in the initiation of blood coagulation, and tissue factor (TF, also known as 
thromboplastin or clotting factor (F) III) initiates this pathway. Ang II may increase TF 
expression in monocytes, endothelial cells (EC) and in vascular smooth muscle cells (VSMC) 
(10, 11), and conversely treatment with RAAS blockade can diminish TF in plasma and in 
monocytes (12). We have reported that infusion with Ang II induces thrombocyte activation 
acutely (13). Also platelets have been shown to possess receptors for Ang II, angiotensin type 
1 receptor (AT1R) subtype, but the cinical importance of these receptors is not known. TF is 
accepted as the initiator of coagulation, and the amount of TF exposure will predict whether 
or not clotting will occur. It has been assumed that an increased expression of TF is an 
adaptive defence mechanism that aims to facilitate haemostasis at sites of injury, but these 
mechanisms can contribute to a prothrombotic state in a number of diseases. 
Accumulating evidence indicates an association between hypercholesterolemia and activation 
of the RAAS in the progress of atherosclerosis (14). Exposure of Ang II to 
hypercholesterolemic animals has been reported to be potently proatherogenic, and data 
strongly suggest that Ang II potentiates atherosclerosis in experimental models of 
hyperlipidaemia (7, 15). Conversely, it seems that ACE inhibitors offer vasoprotective effects 
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by reducing atherosclerosis, and this is well documented in animal experiments (16-18) and 
in large human trials (9, 19, 20). In addition, studies have shown that Ang II has important 
effects with regard to oxidation of low-density lipoprotein (LDL) cholesterol in the vessel 
wall (16), and on macrophage uptake of oxidized (ox) LDL cholesterol and entry into vessels 
(21).  
A common primary lipid disorder in humans is FCHL (phenotype IIb according to the 
Fredrickson classification) (22), defined by an elevation of triglycerides and cholesterol in 
combination with reduced plasma HDL cholesterol. Patients with FCHL also exhibit elevated 
very low density lipoprotein (VLDL) cholesterol and small dense LDL cholesterol. FCHL 
has an association with insulin resistance, impaired endothelial reactivity, hypercoagulability, 
impaired fibrinolysis and systemic inflammation (23-27). Familial hypercholesterolemia (FH) 
(phenotype IIa according to the Fredrickson classification) (22) is less common and is 
characterized mainly by elevated total and LDL cholesterol. FH exhibits impaired endothelial 
reactivity (28) and a prothrombotic state without influence on fibrinolysis (29, 30). Together, 
FCHL and FH phenotypes account for about half of the primary lipid disorders. 
The present research program was set up to investigate whether activation of RAAS in 
hypertensive patients has an impact on inflammation and haemostasis. We also wanted to 
clarify if the potential effects blocking the RAAS on inflammation and haemostasis were due 
to the antihypertensive effect per se. Patients with FCHL have a different phenotype as 
compared to FH. Both conditions have a poor vascular outcome and are recognized by 
impaired endothelial reactivity, but otherwise different characteristics regarding inflammation 
and haemostasis. We therefore studied the inflammatory and haemostatic responses to Ang II 
stimulation in these subjects separately.  
1.2 INFLAMMATION IN VESSELS 
Atherosclerosis is nowadays considered a disease caused by a chronic inflammation, 
associated with ED (31). Low-grade inflammation contributes to atherosclerosis, and 
several mediators of inflammation are up-regulated in subjects with atherosclerotic disease 
(31). Among the markers of inflammation for diagnostic use, the cytokines interleukin (IL)-
6, and in particular C-reactive protein (CRP), have generated considerable attention. CRP is 
generated by hepatic cells and is modulated by IL-6, but also by the cytokines tumor 
necrosis factor (TNF)-α and IL-1 (32), thereby contributing to the up-regulation of 
monocyte chemoattractant protein-1 (MCP-1) and selectins, such as P- and E-selectins and 
cell adhesion molecules, such as intracellular adhesion molecule -1 (ICAM-1) and cell 
adhesion molecule-1 (VCAM-1). CRP attenuates the synthesis of endothelial nitric oxide 
(NO) (33), and causes augmented plasminogen activator inhibitor-1 (PAI-1) (34). Increased 
concentrations of acute phase reactants like CRP, IL-6, leukocyte count and fibrinogen are 
all associated with an increased risk of CVD (35-37). Phospholipase A2, which is 
implicated in the oxidation of LDL and subsequent oxidative stress and inflammation, can 
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predict atherosclerotic disease (38). These data clearly support a pivotal role for cytokines in 
the inflammatory process in early stages of atherogenesis. 
Inflammatory mediators have been associated with components of metabolic disturbances, 
and cytokines might be a link between dysregulated metabolism and inflammation, as CRP, 
fibrinogen and IL-6 are closely related to the metabolic syndrome (32). 
1.3 ENDOTHELIAL DYSFUNCTION AND ATHEROSCLEROSIS 
The endothelium has an important function in preserving a physiological structure and 
function. Healthy, intact endothelium exhibits a thromboresistant, protective surface 
between the vascular lumen and VSMCs in the vessel wall, with the lamina elastic interna in 
between. In particular, a normally functioning endothelium prevents platelet adhesion (39). 
ECs form a monolayer that produces factors that regulate vascular tone, inflammation, 
haemostasis, vascular cell growth and death, angiogenesis and the migration of leukocytes. 
Vascular tone is dependent on a delicate balance between vascular dilators, such as NO, 
and vascular constrictors, such as Ang II. Also, VSMCs are affected by ECs and other 
factors, and VSMCs can themselves release cytokines and growth-regulatory mediators, 
which in turn have an impact on vessel phenotype and growth.  
1.3.1 Oxidative stress 
In 1985, Sies described oxidative stress as an imbalance between anti- and prooxidants, 
with a subsequent increase of reactive oxygen species (ROS) bioavailability, leading to 
tissue damage (40). An important factor of the biology of ECs is the cell reduction-
oxidation reaction (redox) state. A molecule of particular importance in endothelial 
function is NO. The traditional risk factors for CVD can initiate ED by changing the cell 
redox state and, consequently, the oxidative stress in the vascular wall. 
The ratio between ROS and NO regulates the redox state and is of vital importance for 
proper function of the vascular endothelium. Increased generation of superoxide anion, •O2 
and, subsequently, oxidative stress result in an enhanced catabolism of NO, which leads to 
ED and impaired vasodilatation. ROS also has the ability to reduce the activity of NO 
synthase (NOS) and to increase the breakdown of NO. Also, NO is a potent endogenous 
inhibitor of VSMC migration and growth (41) and impairs the up-regulation of adhesion 
molecules and cytokines (42). The transcription of the pleiotropic nuclear factor kappa-light-
chain-enhancer of activated B-cells (NF-ҡB) has a pivotal role in endothelial up-regulation of 
cytokines and adhesion molecules, and NO is a powerful inhibitor of activation of NF-ҡB 
(43). It is to be noted that NO and the superoxide anion react to form the powerful oxidant 
peroxynitrite, ONOO-, that can damage ECs. ROS also lowers the availability of 
tetrahydrobiopterin. If the latter occurs, the oxygenase function of NOS is replaced by its 
reductase function and ROS are produced instead of NO, which increases NF-ҡB activity, 
and the expression of cytokines (42). An imbalance between NO and ROS increases the 
risk for vasospasm, VSMC proliferation, proinflammatory and prooxidant states and ED 
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can create an imbalance between tissue plasminogen activator (t-PA) and PAI-1 and may 
predispose a prothrombotic state. 
Oxidative stress up-regulates and activates redox-sensitive genes for chemokines (such as 
MCP-1) and vascular adhesion molecules (such as VCAM-1 and ICAM-1). The superoxide 
anion may mediate increased activity of NF-ҡB that has a vital function in up-regulating 
these proinflammatory genes (44). As a consequence of this activity, leukocytes interact 
with the endothelium, and subsequently transmigrate into the subendothelial layer of the 
vessel wall. After transmigration of the leukocytes, cytokines (such as IL-6) are released, 
resulting in recruitment of additional monocytes. In the vessel wall, monocytes subsequently 
differentiate into macrophages. Via the scavenger receptors, macrophages take up oxLDL 
and are then transformed into foam cells, present in the early stages of atherosclerosis. As 
the plaque progresses at inflammatory sites, macrophages and other migrating cells, as well 
as activated ECs, produce cytokines and matrix metalloproteinases, eventually causing the 
plaque to rupture.  
1.3.2 Recruitment of leukocytes, platelet dependent 
ED may be defined as an imbalance between, on the one hand vasodilating, and on the 
other hand vasoconstricting substances, produced by the endothelium (45). Current 
concepts of atherogenesis include involvement of platelets, the immune system and chronic 
inflammation (46).  
The healthy endothelium controls platelet activity through inhibitory mechanisms, while a 
systemic inflammatory environment induces ECs to develop a phenotype that make them 
adhesive for platelets (47). Numerous studies have shown that platelets have the ability to 
adhere to the intact ECs and also to modulate their function. Thus, exposure of the 
subendothelial surface, as in plaque rupture, is not necessary for platelet adhesion to 
vascular cells. Activated platelets release mediators and growth hormones, which will 
induce up-regulation of adhesion molecules and the release of chemoattractants that, in 
turn, regulate the adhesion and subsequent transmigration of leukocytes into the vessel 
wall. It is important to take into account when analysing platelets in animal models that 
human platelets differ from platelets in for example the mouse in many important ways 
(such as difference in expression of surface receptors, higher platelet count), and the results 
in animal experiments can not be uncritically applied to the human situation (39). 
The contact between platelets and the inflamed ECs is accomplished by the binding of 
endothelial P-selectin  to glycoprotein (GP) Ib/IX/V (also referred to as the von Willebrand 
factor (vWF) receptor complex). Platelet-selectin glycoprotein ligand-1 (PSGL-1), 
interacting with P-selectin, present on leukocytes and to a minor degree also on platelets, 
mediates rolling of platelets to ECs under high shear stress. However, the association 
between PSGL-1/GPIb/IX/V and P-selectin is insufficient for a stable and durable 
adhesion. The firm and long-lasting binding of platelets to ECs is mediated through the β3 
integrins αIIbβ3 (GPIIbIIIa) and αvβ3, the vitronectin receptor.  
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Adherent platelets undergo a series of alterations, both morphological and biochemical, 
leading to release of potent proinflammatory and mitogenic substances, such as IL-1β, IL-8, 
cluster of differentiation (CD) 40L, platelet factor 4, thromboxane A2 (TXA2), platelet-
derived growth factor, platelet activating factor (PAF) and regulated on activation, normal T 
cell expressed and secreted (RANTES), thereby changing the phenotype of the ECs into a 
chemotactic, adhesive, and proteolytic state. The changes of the ECs, induced by platelets, 
will support chemotaxis, and subsequently adhesion of monocytes to the inflammatiory 
sites (48). Activated platelets also secrete glycosaminoglycans (GAG)s that contribute to 
the immobilization of chemokines and the adhesion and transmigration of leukocytes (49).  
The firm adhesion of neutropils to platelets is facilitated by macrophage antigen-1 (MAC-1 
or αMβ2) activation, induced by P-selectin/ PSGL-1 and augmented by platelet 
chemokines, arachidonic acid metabolites and inflammatory lipids. The interaction between 
MAC-1 and platelet surface ligands (ICAM-2), GPIb/IX/V and αIIbβ3-bound fibrinogen) 
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Figure 2. Recruitment of leukocytes, platelet dependent. Leukocytes can be recruited to 
inflamed endothelial cells through interaction with platelets. The first contact by rolling of 
platelets on endothelial cells is mediated by interaction of endothelial P-selectin to platelet 
PSGL-1 or GPIb/IX/V, respectively. Firm binding is then mediated through the β3 integrins. 
Adherent platelets release inflammatory substances, which support chemotaxis and 
adhesion of monocytes. The β2 integrin, MAC-1 have a dominant role in promoting stable 
leukocyte-platelet interaction. GP, glycoprotein; ICAM, intracellular cell adhesion molecule;  
LFA, lymphocyte function-associated antigen; PSGL, platelet-selectin glycoprotein ligand; 
MAC, macrophage antigen; vWF, von Willebrand factor; αvβ3, the receptor for vitronectin 
and αIIbβ3, also called GP IIbIIIa. Figure modified from Ghasemzadeh M, 2012 (58). 
Following integrin priming by selectins, and subsequently slow rolling, chemokines on 
neutrophils induce a rapid activation of integrins (59). The key role of the β2-integrins is 
well established. Leukocyte adhesion and transmigration at inflammatory sites is dependent 
on the β2-integrin ligation of MAC-1 and LFA-1 on leukocytes, with their specific ECs 
ligands, ICAM-1 and ICAM-2 (60). Also, the β1-integrin very late antigen 4, VLA-4 or 
α4β1, and its major endothelial counter-receptor VCAM-1, have an important role in 
monocyte and lymphocyte arrest. Figure 3 illustrates platelet independent recruitment of 
leukocytes. 
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Figure 3. Recruitment of leukocytes, platelet independent. Leukocytes can adhere to 
inflamed endothelial cells through specific interaction with endothelial cells. At first, rolling 
is initiated by binding of selectins with their receptors, while firm attachment is mediated by 
the leukocytes-expressed MAC-1 and LFA-1 (β2-integrins) and by VLA-4 (a β1-integrin). 
VCAM, vascular cellular adhesion molecule; ICAM, intracellular cell adhesion molecule; 
LFA, lymphocyte function-associated antigen; MAC, macrophage antigen; PSGL, platelet-
selectin glycoprotein ligand and VLA, very late antigen. Figure modified from Ghasemzadeh 
M, 2012 (58). 
1.4 THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM  
The RAAS is a dynamic physiologic system and is central in regulating the balance of fluids 
and electrolytes and blood pressure (BP). All RAAS peptides are derived from 
angiotensinogen. Renin, the rate-limiting enzyme is produced in the kidney (juxtaglomerular 
cells), and is released in response to vasodilation or low sodium. Renin cleaves 
angiotensinogen into Ang I. ACE hereafter cleaves Ang I to generate Ang II, which is the 
predominant peptide of the RAAS (61).  
Ang II primarily exerts its influence through the receptors AT1R and AT2R. A number of 
signalling pathways are activated when Ang II interacts with AT1R and AT2R. The main 
AT1R-mediated Ang II effects include vasoconstriction by VSMC stimulation, sodium 
retention in the kidneys, and aldosterone release from the adrenal cortex (62). AT2R-
mediated effects generally oppose those effects mediated by AT1R, and include 
vasodilatation and anti-inflammatory effects in VSMCs, but also anti-proliferative effects in 
the myocardium (63). Figure 4 summarizes the different RAAS components. 
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Figure 4. The renin-angiotensin-aldosterone system. Renin is secreted due to various 
stimuli, and then cleaves angiotensinogen into the inactive decapeptide Ang I. Renin and 
prorenin can also interact with (pro) renin receptors to activate the MAP kinases ERK1/2 
and p38 pathways. ACE cleaves Ang I into the octapeptide Ang II, or to Ang-(1-7) by ACE2 
and probably ACE. ACE2 may also produce Ang-(1-7) from Ang II. ACE also inactivates 
bradykinin into inactive fragments. Importantly, Ang II may be generated directly from 
angiotensinogen through non-ACE pathways. Ang II activates AT1R, a G protein-coupled 
receptor. Vasoconstriction and stimulation of aldosterone tend to elevate blood pressure. 
Ang II also activates AT2R, a G protein-coupled receptor, which can antagonize the effects 
of activation of the AT1R. Ang, angiotensin; ACE, angiotensin converting enzyme; MAPK, 
mitogen-activated protein kinase; extracellular signal regulated kinase, ERK; angiotensin 1 
type receptor, AT1R; angiotensin 2 type receptor, AT2R; (P)RR, (pro)renin receptor; c-Src, 
cellular Src kinase, a non-receptor tyrosine kinase; SHP-2, Src-homology 2 domain-
containing phosphatase 2; NO, nitric oxide; NEP, neutral endopeptidase and PEP, prolyl 
endopeptidase. 
1.4.1 The ACE2-Ang-(1-7)-Mas axis 
Studies have identified a number of angiotensinogen derived peptides and their receptors 
(figure 4). Ang-(1-7) is derived from Ang II through the influence of ACE2. Then Ang-(1-
7) exerts its effect via the Mas receptor (64). The axis of ACE2-Ang-(1-7)-Mas may lead to 
vasodilatation via activation of NO, and decreased fibrosis, thereby enhancing the effect of 
ACE inhibitor blockade of Ang II (65). Ang-(1-7) also mediates anti-inflammatory and 
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anti-thrombotic effects (66) via activation of NO and inhibition of ROS, derived from 
nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase (Nox) (67). Increased 
Ang-(1-7) has been associated with a favourable phenotype, with attenuated inflammation 
in atherosclerotic plaques (68). In summary, the ACE2-Ang-(1-7)-Mas axis appears to work 
as a system of opposite effects, that may have the ability to complement the ACE-Ang II-
AT1R axis. 
1.4.2 Aldosterone 
Aldosterone is produced in the adrenal cortex and acts on sodium reabsorption in the 
kidney. Common stimuli are Ang II, high plasma levels of potassium and 
adrenocorticotropic hormone. Aldosterone is also implicated in vascular inflammation, 
oxidative stress, fibrosis, remodelling and ED, particularly in the presence of salt (69). 
Conversely, vascular remodelling effects are reduced by the use of mineralocorticoid 
receptor (MR) blockers (70). In VSMCs and in ECs, aldosterone exerts its effects via 
mitogen-activated protein (MAP) kinase (also known as extracellular signal regulated 
kinase (ERK)), c-Src (cellular Src kinase, a non-receptor tyrosine kinase), and participates 
in epidermal growth factor receptor transactivation (71, 72) (figure 5). Aldosterone induced 
increase in oxidative stress in VSMCs may also have an impact on ED through a reduction 
in NO bioavailability (72). Vascular inflammation in ECs is promoted by aldosterone 
induced expression of ICAM-1 and adhesion of leukocytes in an MR dependent manner 
(73). 
There is cross-talk between aldosterone and Ang II in VSMCs. Aldosterone increases the 
expression of AT1R in vivo (74), and Ang II stimulates aldosterone synthesis by the 
adrenal gland.   
There are synergistic effects between aldosterone and Ang II on VSMC proliferation (75), 
migration (76), constriction (77) and senescence (78). The synergistic effect of aldosterone 
and Ang II in VSMC proliferation is a very rapid response, already after 5 minutes. This 
response is compatible with a non-genomic and MR dependent pathway via activation of 
AT1R and transactivation of epidermal growth factor receptor. A second peak, between 2 
and 4 h, is compatible with a genomic pathway. Aldosterone injections in healthy subjects 
induce a rapid (within 10 minutes) increase in vascular resistance (79).  
The G protein oestrogen receptor (GPER) is the principal mediator of oestrogen effects, but 
studies have reported that aldosterone is a much more potent agonist at GPER than 
oestrogen (80). GPER is a widely expressed receptor in cardiovascular tissues, and is 
present in the heart, in the ECs (81) and in VSMCs. GPER has been shown to mediate 
vasodilatation and to lower BP, and the vasodilator effects appears to be EC dependent, 
secondary to activation to phosphatidylinositol 3-kinase and NOS (80). The endothelial 
dependent vasodilatation seems to be a function of gender, age, or both, with a strong 
impact in premenopausal women, and a weak influence in men. MR antagonists may also 
act as GPER antagonists (80).  
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Figure 5. Aldosterone exerts its effects via a non-genomic or a genomic action. Non-
genomic pathways are MR dependent or independent. In the MR-dependent pathway 
aldosterone induces vasoconstrictor effects via a rapid activation of ERK1/2 through 
transactivation of EGFR and c-Src. C-Src also induces ROS production via NOX, and ROS 
activates ROCK and MAP kinase. In the genomic pathway aldosterone binds to the MR 
and translocates to the nucleus of the cell and activates genes, which in turns activates 
ERK1/2. Aldosterone also have vasodilator effetc via GPER activation and a PI3K 
dependent increase in NO activity. MR, mineralocorticoid receptor; ERK, extracellular 
signal-regulated kinase; c-Src, cellular Src kinase, a non-receptor tyrosine kinase; EGFR, 
epidermal growth factor receptor; ROS, reactive oxygen species; ROCK; Rho-associated 
protein kinase; NOX, nicotinamide-adenine dinukleotidfosfat oxidase; VSMC, vascular 
smooth muscle cell; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells; 
GPER, G-protein-coupled oestrogen receptor (also referred to as GPR30, G protein-coupled 
receptor 30); PI3K, phosphatidylinositol 3-kinase; AKT, ak strain transforming (also referred 
to as protein kinase B) and NO, nitric oxide. Figure modified from Briet M, 2013 (82). 
The endothelium mediated vasodilation by aldosterone seems to be induced by activation of 
GPER, whereas the vasoconstrictor actions may be dependent on MR activation in VSMCs. 
Thus, the balance between endothelial vasodilator (GPER-mediated) and VSMCs 
vasoconstrictor effects (MR-dependent) appears to be a pivotal determinant of the effect of 
aldosterone on regulation of vascular contractility (83).   
GPER is also expressed in normal hepatocytes and GPER activation increases LDL 
receptor expression and suppresses circulating LDL cholesterol, while oestrogen deficiency 
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increases LDL cholesterol. The clearance of LDL via GPER activation has been linked to 
down-regulated levels of proprotein convertase subtilisin kexin type 9 (84). 
Taken together, GPER seems to influence two of the most important atherosclerotic risk 
factors, hypertension and dyslipidemia, which implies that GPER may influence the 
development of atherosclerotic complications. 
In vivo data have shown that mutual influence between aldosterone-stimulated MR and Ang 
receptor pathways plays a role for vascular effects of aldosterone. The AT1R seems to be 
required for MR-induced ED and vascular remodelling, inflammation and oxidative stress 
(85). Aldosterone has been linked to the metabolic syndrome and obese patients, and in the 
Framingham offspring study aldosterone was a predictor for incidence in the metabolic 
syndrome (86). An association between body weight mass and plasma aldosterone 
concentration has been shown in normotensive overweight patients. (87). Also, aldosterone 
decreases after weight loss (88), and aldosterone might be considered a potential adipocyte-
derived factor since adipocytes have been shown to synthesize aldosterone in an AT1R 
dependent manner (89). 
1.4.3 Renin, prorenin and renin-prorenin receptor 
The RAAS exert effects independent of Ang I and Ang II (figure 4). This includes the 
direct effect of renin and prorenin, its proenzyme inactive form (90). The use of both ACE 
inhibitors and AT1R blockers has been reported to result in an at least 3-fold increase in 
plasma renin activity (91). The (pro) renin receptor may bind both renin and prorenin. The 
active receptor activates the MAP kinases ERK1/2 and p38 pathways. This entails in turn 
cell growth and fibrosis in cardiomyocytes, ECs and VSMCs (92). Inhibition of renin with 
aliskiren (a renin inhibitor) led to reduction in BP, improvements in systemic insulin 
resistance, improved insulin signalling and glucose uptake (93). These improvements were 
also associated with decreased levels of Ang II, aldosterone, AT1R, and consequently 
attenuated oxidative stress and fibrosis. For this reason it is difficult to interpret whether 
these effects were due to direct renin blockade or through decreasing downstream 
components of the RAAS. The exact significance of the (pro)renin receptor still is unclear, 
and a role for this receptor is lacking (94). 
1.4.4 Alternative enzymes that generate Ang II 
The RAAS system is complicated by enzymes (besides renin and ACE) that can generate 
Ang II. Chymase, generated in mast cells, is supposed to be the main enzyme responsible 
for cleaving Ang I into Ang II (95). Ang II can also be formed by direct proteolysis of 
angiotensinogen by a number of other enzymes, such as cathepsin G, tonin and t-PA, but 
the contribution of these enzymes is controversial (96, 97). There are estimates that at least 
40% of Ang II is formed by non-ACE pathways (98). This suggests that full-scale 
suppression of the RAAS is not possible by ACE inhibition alone. 
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1.4.5 Atherosclerosis and the RAAS 
The RAAS is of vital importance in the pathobiology of vascular disease, and convincing 
data indicate that Ang II promotes atherosclerosis (99). Thus, it has been proposed that 
RAAS inhibition may have anti-atherosclerotic effects beyond the effects of the BP 
reduction (9). 
Ang II causes oxidative stress and impaired NO activity. A cascade of intracellular signalling 
responses is initiated when Ang II binds to the AT1R. Ang II is a powerful activator of 
vascular Nox (of which Nox 1, 2, 4 and 5 are present in arteries), that induces the production 
of ROS (superoxide anion and hydrogen peroxide, H2O2) from ECs and VSMCs (100), and 
activation of redox-sensitive kinases (101). Activation of the AT1R induces generation of 
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remodelling as it induces the expression of a number of growth factors in VSMCs (105). Ang 
II has been observed to induce a dose dependent increase in IL-6 in rat VSMCs (106) and to 
modulate vascular cell migration, decrease VSMC apoptosis (107) and alter ECM 
composition (108). Additionally, Ang II may increase TF expression in monocytes, ECs and 
VSMCs (10, 11), and conversely treatment with RAAS blockade can diminish TF in plasma 
and in monocytes (12). Figure 6 summarizes Ang II and its effects in the progression of 
atherosclerosis. 
Some of the clinical effects of ACE inhibition therapy may possibly be caused by interrupting 
Nox-derived ROS. Studies have shown an antioxidant effect of AT1R blockers. Indeed, 
direct inhibition of Nox and others ROS modulators has emerged as an attractive strategy to 
improve ED and vascular damage in hypertensive patients (109).   
1.4.5.1 Antihypertensive therapies addressing inhibition of the RAAS 
Evidence supports a positive effect of RAAS inhibition (110). Some studies suggest that ACE 
inhibitors improve EC function, both in hypertensive patients and in patients with CHD (111, 
112). Large scale studies of ACE inhibition post myocardial infarction (MI) and in heart 
failure demonstrated convincing evidence of reductions in the risk of recurrent MI (19, 20). 
Later, trials were designed to test the hypothesis that ACE inhibition in patients with CVD, 
but no heart failure, reduced the risk of atherosclerotic events. Indeed, the HOPE trial showed 
convincingly that treatment with ramipril in patients with high risk for vascular disease, 
without heart failure, reduced the risk of stroke, myocardial infarction and death (9). The 
EUROPA study demonstrated that treatment with perindopril in patients with stable CHD, 
reduced the risk for cardiovascular events (113). In contrast, the PEACE trial failed to 
confirm that patients with known CHD had a benefit of ACE inhibitors, in addition to modern 
conventional therapy (114). The results in that study might have been due to the low number 
of hard endpoint events (myocardial infarction or death). The lack of efficacy observed might 
simply have been affected by the enrolment of a low-risk population and by a high proportion 
of patients treated by statins (70%), compared to HOPE (29%) and EUROPA (56%). The 
QUIET study also failed to confirm a decrease in overall mortality rate after treatment with 
an ACE inhibitor (115). This outcome may partly have been due to enrolment of a low-risk 
population with both normal LDL cholesterol and body mass index. It is to be noted that, 
both the PEACE and QUIET trials were characterized by a very high proportion of patients 
previously subjected to at least one revascularization procedure (72% and 100%, 
respectively). 
1.5 HYPERTENSION 
Hypertension is globally the most common cause of morbidity and mortality. In the vascular 
system hypertension entails arterial remodelling and ED. Common to these processes are 
alterations in ECs and VSMCs to a vasoconstrictor, mitogenic, profibrotic, promigratory and 
proinflammatory phenotype influenced by oxidative stress.   
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Convincing evidence indicates that patients with hypertension have ED, both in the 
macrocirculation (conduit arteries) and microcirculation (arterioles, 10-150µm, and small 
arteries, 150-300 µm). The microvessels are known to be the main site of vascular resistance. 
Folkow described that already a small reduction in vessel diameter has a major effect on 
resistance, and that this was a result of the Poiseuille´s law (116). Blood vessels undergo 
structural alterations during long-term hypertension. This includes remodelling and 
rarefaction. Remodelling is known to be responsible for the increase in vascular resistance in 
hypertension (117). In small arteries and arterioles remodelling demonstrates a 
rearrangement of the vessel wall without growth that causes a narrowing of the lumen and 
an increased media-to-lumen ratio known as inward eutrophic remodelling. Rarefaction is 
defined as a decrease in the length or small vessel numbers in a defined volume.  
Oxidative stress and ED are associated with both remodelling and rarefaction (117, 118). 
The endothelium may be activated by various stimuli, both chemical and physical. 
Hypertension in otherwise healthy subjects has been related to high levels of sICAM-1 and 
IL-6 (119), indicating that hypertension may contribute to an inflammatory state and to 
atherosclerosis. When stimulated the endothelium releases endothelium-contracting factors 
(EDCF) and endothelium-derived relaxing factors (EDRF), which exert effects on the 
underlying VSMCs. The balance between these factors determines the tone of the VSMCs. 
The most significant EDRF is NO, but also prostaglandin I2 (PGI2, or prostacyclin) and 
endothelium-derived hyperpolarizing factors are important vasodilator signals. The ECs 
secrete several EDCFs. One of the most important is Ang II, but also endothelin and 
cyclooxygenase (COX)-derived prostanoids are significant vasoconstrictors (120). In 
hypertension, oxidative stress induces increased production of the prostanoid TXA2 by 
constitutive (COX-1) and inducible (COX-2) cyclooxygenases, which leads to increased 
vasoconstriction and reduced endothelium-dependent vasodilation (121). It is to be noted that 
COX itself can produce ROS by oxidizing NADPH (121). Hence, ROS are upstream and 
downstream of the COX-prostanoid system. 
During long-term BP elevation the ECs age prematurely and their turnover is accelerated. 
Eventually they are replaced by regenerated ECs (122). Importantly, the replaced 
endothelium has a reduced ability to release EDRFs, and in particular NO. The result of 
blunted NO release is a weakening of the brake to EDCFs and an endothelium-dependent 
contraction (120). This ED in micro- and macrocirculation also entails platelet aggregation, 
up-regulation of adhesion molecules, and growth of VSMCs (122, 123). These changes in the 
ECs contribute to thrombosis, inflammation, vascular remodelling and, in the end, 
atherosclerosis. 
1.5.1 Shear stress and circumferential stretch 
The pulsatile BP causes the blood vessels to be subject to a constant shear stress and 
circumferential stretch. The frictional force during the flow of blood in the vessels causes 
wall shear stress while the pulsation generates circumferential stretch, perpendicular to the 
blood flow. Under physiologic conditions, pulsatile forces with a clear direction (laminar 
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shear stress and circumferential stretch) cause only a transient signalling of proinflammatory 
and proliferative pathways, and these pathways become down-regulated when such directed 
forces are maintained. On the other hand, pathologic conditions with forces that are either too 
high or too low or without a direction (such as disturbed flow and undirected stretch at branch 
points) induce sustained signalling of proinflammatory and proliferative pathways (124). 
How the vessel wall responds to these forces is of vital importance, and a number of 
integrins, receptors and ECM components have been extensively studied (125). 
1.5.1.1 Shear stress 
In linear parts of the vessels the blood flow is laminar and shear stress is directed and high. In 
contrast, in curvatures and branches the blood flow is irregular and disturbed, which results in 
low shear stress. Persistent laminar blood flow and high shear stress protects against 
atherosclerosis by up-regulating the expressions of protective EC genes and proteins. In 
contrast, disturbed flow with low shear stress activates EC genes and proteins promoting 
atherosclerosis.  
The most important flow mediated vasodilator is NO, which is generated from endothelial 
NO synthase; but also PGI2 is an important vasodilator (126).  During steady laminar shear 
stress NO and PGI2 are up-regulated, inducing vasodilatation and inhibition of platelet 
aggregation, and prothrombotic molecules such as TF are down-regulated (127). The main 
inducer of fibrinolysis, t-PA, may be shear stress regulated, and t-PA secretion by ECs 
increases with increasing shear stress (128). Also, thrombomodulin (TM) is up-regulated by 
high shear stress (129). Laminar steady high shear stress has been shown to down-regulate 
AT1R in an NO dependent manner (130). In addition, AT1R antagonists reduce oxidative 
stress in human hypertension (131). 
Low or reversing shear stress predisposes to atherosclerosis. The low flow or flow reversal 
causes the production of superoxides by Nox, which scavenge NO, leading to a decrease in 
NO bioavailability, generation of peroxynitrite and ED. (132). Peroxynitrite reduces 
vasodilation by reducing NO and also by decreasing the bioavailability of PGI2 (by nitration 
of PGI2 synthase) (133). Peroxynitrite also causes endothelial NO synthase uncoupling (by 
oxidizing tetrahydrobiopterin, the cofactor of endothelial NO synthase) (134). Consequently, 
low shear stress induces a proinflammatory and prothrombotic state through several 
mechanisms. 
1.5.1.2 Circumferential stretch 
Elevated BP causes a pressure that is perpendicular to the flow direction, and long-term 
hypertension induces vascular remodelling. This will lead to increased wall thickness and an 
augmented resistance in small vessels. The cardiac pulsative flow generates stretch on both 
ECs and VSMCs.  
An important effect of the pulsatile character of BP is the release of Ang II and a subsequent 
increase of oxidative stress in ECs (135). Studies have also suggested that circumferential 
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stress activates AT1R, without involvement of An II (136). In VSMCs, the mechanical stress 
by circumferential stretch activates integrins through interaction with ECM and results in 
actin polymerization (137).   
1.5.2 Microvascular (capillary) rarefaction 
During chronic hypertension, the endothelium loses its function, and the microvessels will be 
constricted, unperfused and eventually the vessels disappear. This phenomenon is known as 
microvascular rarefaction (138). Rarefaction exists in two subforms (139):  
 Functional rarefaction: Refers to a reduction in the actual number of vessels perfused. 
 Structural rarefaction: Refers to a decrease in the actual number of vessels . 
ED has been shown to be associated with vessel rarefaction (140). During hypertension, 
peripheral resistance is increased by microvascular rarefaction and a significant component of 
the increase in total peripheral resistance may be due to vessel rarefaction (138). 
Imbalanced angiogenesis (i.e. impaired formation of microvessels), contributes to rarefaction, 
and ageing has been shown to be associated with impaired angiogenesis (141). NO has been 
shown to be implicated in angiogenesis, and microvascular rarefaction in hypertension may 
partially be due to reduced angiogenesis because of impaired NO biosynthesis (142). In 
healthy conditions, hypoxia serves as the main trigger for angiogenesis, and chronic hypoxia 
may induce angiogenesis by vascular endothelial growth factor pathways (143). However, in 
CVD with associated decreased NO synthesis, ischemia-induced angiogenesis is generally 
impaired (144). 
1.5.2.1 Antihypertensive therapies addressing rarefaction 
Few studies have focused on how antihypertensive drugs affect the microvasculature. Studies 
have shown that long-term treatment with various antihypertensive drugs normalize vascular 
structure and reverse rarefaction (145). One study compared the effect of treatment with an 
ACE inhibitor and a calcium channel blocker (CCB) on the retinal microvasculature. 
Treatment was associated with improvement in vessel narrowing and rarefaction, and no 
differences were observed between the treatment regimens (146). In another study, an ACE 
inhibitor restored the structure of arterioles and small arteries in hypertensive subjects, 
whereas a β-blocker did not (147). The ability to normalize the structure in the microvessels 
might be restricted to drugs with vasodilator capacity, such as ACE inhibitors and angiotensin 
receptor blockers (ARB)s, excluding drugs reducing cardiac output, such as β-blockers and 
diuretics (145). In support for this assumption are two studies with increased vascular area 
and capillary density during treatment with prazosin, an alpha 1-adrenoceptor blocker (148, 
149), but the results are inconclusive, since doxazosin, another alpha 1-adrenoceptor blocker 
inhibited EC adhesion, migration and invasion (150). The drug class ARB also has 
vasodilator capacity and can increase microvessel density. In a LIFE substudy, the ARB 
losartan reduced vascular rarefaction and hypertrophy, compared to a β-blocker (151). 
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The proangiogenic contribution of ACE inhibitors on rarefaction has been examined in 
animal models, and drugs targeting the RAAS induce angiogenesis in most animal studies. 
These effects are probably mediated by bradykinin, and the generation of pathways including 
NO and vascular endothelial growth factor (139).  
1.5.3 Hypertension and endothelial dysfunction and the RAAS 
Derangements of the RAAS contribute to elevated BP and target-organ damage. Chronic 
inflammation in the vessel is considered to be the link between hypertension and 
atherosclerosis, but evidence of a causal link between oxidative stress and hypertension is not 
convincing, and definitive proof is still lacking.  
Activation of the RAAS is a major cause of hypertension. Studies in essential hypertension 
have demonstrated that systolic and diastolic BP relate positively with biomarkers of 
oxidative stress and negatively with antioxidant levels (152). Vascular Nox activity is 
increased in hypertension and is highly sensitive to Ang II and aldosterone. In small arteries 
of hypertensive patients, the ECs and VSMCs expression of Nox 1, 2, 4 and 5 generate 
increased production of ROS (153). Measurements of ROS production in VSMCs 
resistance arteries of hypertensive patients have shown increased levels of superoxide anion 
and hydrogen peroxide and up-regulated Ang II-stimulated redox signalling, when 
compared to conditions in normotensive subjects (154).  
1.5.3.1  Antihypertensive therapies addressing endothelial dysfunction 
Interpretation of the effects on ED of ACE inhibitors and other antihypertensive drugs are 
confounded by the simultaneous reduction in BP as decreased BP per se may have the 
ability to reduce atherosclerotic events. 
Intravenous administration of the ACE inhibitor perindopril restored normal coronary 
artery vascular response to endothelial stimuli in hypertensive patients (111). In agreement, 
the TREND study showed that the ACE inhibitor quinapril decreased vasoconstriction to 
acetylcholine in coronary arteries in subjects with known CHD (112). Perindopril increased 
FMD in hypertensive patients, while the other antihypertensive agents did not (CCBs, first 
and third generation β-blocker and ARB). Perindopril but also CCBs and ARB reduced 
oxidative stress and increased plasma antioxidant capacity (155). These findings are in 
accordance with the BANFF study. This study demonstrated that quinapril improved FMD 
in patients with CHD. On the other hand, no change was seen with the other 
antihypertensive drugs (156). In two studies comparing ARB to CCBs, the reduction in BP 
was equivalent, while the ARB reduced atherosclerosis, and the CCBs did not (157, 158). 
In yet another study comparing an ARB with a CCB in hypertensive patients, the group 
receiving ARB demonstrated improved endothelial function and an associated reduction in 
oxidative stress. The CCB did not have this effect (159). One study examined the effects of 
inhibiting the RAAS by comparing ACE inhibition to ARB in hypertensive patients with no 
effects on markers for inflammation, coagulation, or endothelial function (160). 
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1.6 HYPERLIPIDAEMIA 
Hyperlipidaemia is known as an excess of lipoproteins in the blood, consisting of cholesterol, 
cholesterol esters, apolipoproteins, phospholipids, and triglycerides. Based on density, they 
are divided into five major classes, (Table 1).  
Table 1. The five lipoprotein classes, sorted by increasing density. 
Class of 
lipoprotein 
CM VLDL IDL LDL HDL 
Density (g/mL) < 0.940 0.940-1.006 1.006-1.019 1.019-1.063 1.063-1.210 
Major 
apolipoproteins 
B48, C, E B100, C, E B100, E B100 A, C, E 
Diameter    
(nm) 
80-1200 30-80 25-50 18-28 5-15 
Free chol-
esterol (wt %) 
1-3 4-8 4-8 6-8 3-5 
Cholesterol 
esters (wt %) 
2-4 16-22 20-26 45-50 15-20 
Phospholipid 
(wt %) 
3-6 15-20 20-24 18-24 26-32 
Triacylglycerol 
(wt %) 
80-95 45-65 26-36 4-8 2-7 
CM, chylomicrons; VLDL, very-low-density lipoprotein; IDL, intermediate-density lipoprotein; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein and wt, weight. 
Primary hyperlipidaemias are genetic disorders, while secondary hyperlipidaemias arise due 
to endogenous or exogenous causes. Endogenous causes can be disorders like diabetes 
mellitus, thyroid disease, kidney disease, liver disorders or Cushing’s disease. Exogenous 
causes are obesity, lack of exercise, unfavourable diet or excessive alcohol consumption.  
Primary (or familial) hyperlipidaemias are classified into five different types according to the 
Fredrickson classification (22), which was later adopted by the WHO (Table 2). 
1.6.1 Familial combined hyperlipidaemia 
FCHL is a common inherited cause of hypercholesterolemia caused by a number of gene 
polymorphisms (161). The prevalence of FCHL is estimated to be 0.5-2.0%, and the 
prevalence of CHD in patients less than 60 years old is estimated to be as high as 20% (162). 
FCHL is characterised by increased levels of apolipoprotein B100 containing lipoproteins: 
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Table 2. Primary (or familial) hyperlipidaemias according to the Fredrickson classification. 
Phenotype 
Lipoproteins 
elevated 
Cholesterol 
concentration 
Triglyceride 
concentration 
Frequency 
(%) 
I Chylomicrons Normal to ↑ ↑↑↑↑ <1 
IIa LDL ↑↑ Normal 10 
IIb LDL and VLDL ↑↑ ↑↑ 40 
III IDL ↑↑ ↑↑↑ <1 
IV VLDL Normal to ↑ ↑↑ 45 
V 
VLDL and 
chylomicrons 
↑ to ↑↑ ↑↑↑↑ 5 
VLDL, very-low-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density 
lipoprotein and HDL, high-density lipoprotein.   
VLDLs, intermediate-density lipoproteins (IDLs) and LDLs. FCHL is frequently associated 
with reduced HDL cholesterol, and insulin resistance (163, 164). Also, patients with FCHL 
have a predominance of small dense LDL cholesterol, which is a diagnostic indicator for 
CHD risk (165). VLDL activates NF-ҡB in vivo and in vitro, and this is associated with an 
augmented expression of NF-ҡB-regulated molecules like ICAM-1, VCAM-1 and TNF-α 
(25). VLDL and remnant particles may induce a procoagulant phenotype mainly by 
increasing platelet activation (166). FCHL is characterized by impaired endothelium 
reactivity and hypercoagulability (23, 167), increased PAI-1 levels and a chronic 
inflammation (25-27). Thus, patients with FCHL exhibit ED, disturbed coagulation, impaired 
fibrinolysis and on-going chronic inflammation. These characteristics can all be responsible 
for the increased incidence in cardiovascular events in FCHL subjects.         
1.6.2 Familial hypercholesterolemia 
FH is a disorder that is caused mainly by genetic disturbance in the receptor for LDL, and 
inherited by an autosomal dominant pattern. The LDL receptor (LDLR) function is disturbed 
and the levels of LDL are dramatically increased (168). The heterozygous condition affects at 
least 1 in 500 individuals (0.2%). Patients with FH are affected by increased CHD and 
premature death (168). If not treated, about 50% of men and 20% of women are expected to 
develop CHD before the age of 50 years (168).  
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FH is associated with impaired endothelial reactivity (28), and hyperactive platelets in 
humans (169). Hypercholesterolemia has been shown to exhibit a prothrombotic state without 
any influence on fibrinolysis (29, 30). The cause of the procoagulant state is unknown, but 
one mechanism might be that elevated levels of oxLDL in FH have been shown to cause an 
increase the expression of active TF in human monocytes (11, 170). In one of these studies 
the authors found that TF inhibition reduced the levels of IL-6, indicating crosstalk between 
inflammation and coagulation during FH. They proposed that oxLDL may lead to induced 
expression of both TF and IL-6, and the development of a prothrombotic and 
proinflammatory state. Consistent with these studies, patients with high LDL concentrations 
exhibited an increased TF plasma activity (171). Accumulating evidence demonstrates that 
hypercholesterolemia activates the RAAS, and one possible mechanism might be the 
observation that oxLDL up-regulates ACE and AT1Rs (172). Also, studies have shown that 
hypercholesterolemia is associated with hypertension (173). FH is not associated with insulin 
resistance (174). 
1.6.3 Hyperlipidaemia and the RAAS 
The first sign of atherosclerosis is the fatty streaks that appear during the first or second 
decade of life. The exact mechanisms are unclear, but according to the oxidation hypothesis 
of atherosclerosis, LDL transmigrates from the lumen into the vessel wall. The LDL 
particle is retained when it undergoes oxidative modification by ROS or enzymes (175). 
OxLDL has itself proinflammatory effects and stimulates proinflammatory signalling 
pathways (176). OxLDL may also activate ECs and stimulate the up-regulation of vWF and 
adhesion molecules. The presence of chemokines like MCP-1 attracts leukocytes into the 
intima that promotes an activation of the immune system. Leukocytes are continuously 
recruited into the subendothelial area, and monocytes then differentiate into macrophages. 
In the vessel wall, macrophages take up oxLDL via the scavenger receptors, a process that 
eventually leads to the transformation of macrophages into foam cells (177).  
In VSMCs, oxLDL interacts with Toll-like receptors (TLR) 4 and CD36, which enhances 
the production of cytokines, chemokines and growth factors, resulting in recruitment 
monocytes and differentiation of macrophages (178).    
Lectin-like oxidized LDLR (Lox-1) is a receptor on inflamed ECs and VSMCs, promoting 
the uptake of oxLDL. The activation of Lox-1 is stimulated ROS, oxLDL and Ang II (179). 
Lox-1 also causes an up-regulation of the AT1R (180), demonstrating a potential cross-talk 
between Lox-1 and AT1R. 
Both LDL and oxLDL can activate the RAAS and their receptors in human ECs (172), and 
hypercholesterolemia and elevated Ang II levels in hypertension can accelerate the 
development of ED and atherosclerosis (181). These data indicate a link between 
hypercholesterolemia, hypertension and atherosclerosis. 
Other lipoproteins, such as the triglyceride-rich lipoprotein VLDL and IDL also have 
considerable atherogenic potential (166). These lipoproteins may undergo oxidative 
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modification like that of LDL, and some evidence suggests that VLDL particles may have 
inflammatory effects in vascular cells (25). 
1.7 INSULIN RESISTANCE 
Insulin resistance is a disorder in which the body fails to respond to insulin and exhibits 
dysregulated insulin stimulated uptake of glucose in skeletal muscle and adipocytes, leading 
to high levels of insulin and blood glucose. Insulin resistance is a risk for type 2 diabetes. The 
prevalence of insulin resistance is increasing globally, in particular in hypertensive and obese 
subjects.  
Insulin is secreted from pancreatic β-cells as a result of glucose stimulus. When insulin binds 
to the insulin receptor a series of intracellular events takes place, referred to as the insulin 
signalling cascade. It all culminates in glucose transporter type-4 (GLUT-4) translocation, 
from the cytoplasm to the cell membrane (figure 7). GLUT-4 translocation involves 
downstream signalling via the insulin receptor and insulin receptor substrate-1 pathway, but 
also through phosphatidylinositol 3-kinase and ak strain transforming (AKT, also referred to 
as protein kinase B) pathway (182).  
Most insulin resistance states are a consequence of defects in the upstream signalling 
pathway. Insulin resistance seldom exists isolated; instead it often coexists with other 
cardiovascular risk factors, the metabolic syndrome in particular(183).   
1.7.1 Insulin resistance and the RAAS 
Clinical trials implicate that the RAAS has a potential role in insulin resistance as well as in 
type 2 diabetes, while blockade of the RAAS has been shown to prevent both states (9, 184, 
185). A meta-analysis has shown that ARB and ACE inhibitors decrease the incidence of new 
onset diabetes by 23% and 27%, respectively (186). Ang II stimulation of AT1R results in 
vasoconstriction and a decrease in microvascular blood flow, and these hemodynamic 
changes attenuate the delivery of both glucose and insulin to skeletal muscle. Data also 
indicates that Ang II mediates its effects by direct, non-hemodynamic actions. The activation 
of AT1R by Ang II induces ROS by Nox. ROS on its own, or by activating MAP kinase or 
NF-κB signalling, then inhibits the insulin signalling pathway. The result is inhibition of the 
translocation of GLUT-4, which remains in the cytoplasm (figure 7). 
1.7.1.1 The ACE2-Ang-(1-7)-Mas axis 
Studies have shown that Ang-(1–7), which mediates its effect by interacting with the Mas 
receptor, has a positive regulatory impact on insulin signalling via stimulation of AKT 
(187). Hence, the balance between the two axes ACE-Ang II-AT1R and ACE2-Ang-(1-7)-
Mas is a crucial factor in insulin resistance, and a ratio of the peptides Ang II and Ang-(1-7) 
is likely to be a determinant of the overall activity. 
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Figure 7. Ang II inhibits the insulin signalling pathway. RAAS induce hemodynamic 
changes, i.e. vasoconstriction and reduced blood flow in microvessels, but also non-
hemodynamic action, while causing the formation of ROS, oxidative stress and 
subsequently insulin resistance. The axis of ACE-Ang II-AT1R augments an increase in 
ROS and inhibits the insulin signalling pathway, causing inhibited translocation of GLUT-4. 
Conversely, the axis of ACE2-Ang-(1–7)-Mas shows a positive regulatory effect on insulin 
signalling via stimulation of AKT. Hence, the balance between these two arms is a crucial 
factor in insulin resistance. Ang, angiotensin; RAAS, renin-angiotensin-aldosterone 
system; PI3K, phosphatidylinositol 3-kinase; AKT, ak strain transforming or protein kinase 
B); ROS, reactive oxygen species; NF-κB, nuclear factor kappa B; Nox, NADPH oxidase; 
MAPK, mitogen-activated protein kinase; AT1R, angiotensin type 1 receptor; Ang-(1-7), 
angiotensin-(1-7); IRS, insulin receptor substrate; ARB, angiotensin receptor blocker; ACE, 
angiotensin converting enzyme and GLUT, glucose transporter. Figure modified from 
Henriksen EJ, 2013 (188). 
1.7.1.2 Aldosterone 
Aldosterone interferes directly with insulin signalling. Indeed, studies have shown that 
aldosterone may predict the development of insulin resistance. In the vasculature, MRs have 
been described on both ECs and VSMCs (73). Activation of the AT1R is the primary 
stimulator of adrenocortical release of aldosterone, and inhibition of RAAS by ACE 
inhibitors or ARBs decrease plasma aldosterone levels, while dietary salt restriction increases 
aldosterone production and vascular insulin resistance (189). Excess aldosterone and 
consequently MR activation reduces NO production and increases ROS, leading to ED, 
VSMC hypertrophy, fibrosis and inflammation (190).  
Aldosterone has inhibitory effects on insulin signalling by inducing insulin resistance in 
VSMCs through insulin receptor substrate-1 expression and AKT signalling (191). In ECs, 
 
23 
 
 
Figure 7. Ang II inhibits the insulin signalling pathway. RAAS induce hemodynamic 
changes, i.e. vasoconstriction and reduced blood flow in microvessels, but also non-
hemodynamic action, while causing the formation of ROS, oxidative stress and 
subsequently insulin resistance. The axis of ACE-Ang II-AT1R augments an increase in 
ROS and inhibits the insulin signalling pathway, causing inhibited translocation of GLUT-4. 
Conversely, the axis of ACE2-Ang-(1–7)-Mas shows a positive regulatory effect on insulin 
signalling via stimulation of AKT. Hence, the balance between these two arms is a crucial 
factor in insulin resistance. Ang, angiotensin; RAAS, renin-angiotensin-aldosterone 
system; PI3K, phosphatidylinositol 3-kinase; AKT, ak strain transforming or protein kinase 
B); ROS, reactive oxygen species; NF-κB, nuclear factor kappa B; Nox, NADPH oxidase; 
MAPK, mitogen-activated protein kinase; AT1R, angiotensin type 1 receptor; Ang-(1-7), 
angiotensin-(1-7); IRS, insulin receptor substrate; ARB, angiotensin receptor blocker; ACE, 
angiotensin converting enzyme and GLUT, glucose transporter. Figure modified from 
Henriksen EJ, 2013 (188). 
1.7.1.2 Aldosterone 
Aldosterone interferes directly with insulin signalling. Indeed, studies have shown that 
aldosterone may predict the development of insulin resistance. In the vasculature, MRs have 
been described on both ECs and VSMCs (73). Activation of the AT1R is the primary 
stimulator of adrenocortical release of aldosterone, and inhibition of RAAS by ACE 
inhibitors or ARBs decrease plasma aldosterone levels, while dietary salt restriction increases 
aldosterone production and vascular insulin resistance (189). Excess aldosterone and 
consequently MR activation reduces NO production and increases ROS, leading to ED, 
VSMC hypertrophy, fibrosis and inflammation (190).  
Aldosterone has inhibitory effects on insulin signalling by inducing insulin resistance in 
VSMCs through insulin receptor substrate-1 expression and AKT signalling (191). In ECs, 
 24 
aldosterone and MR activation increase expression of ICAM-1 and Nox-4, leading to 
oxidative stress and decreased NO bioavailability (73). Hypertension and obesity are 
associated with insulin resistance. Aldosterone has also been shown to reduce insulin 
secretion directly in pancreatic cells (192).  
1.7.1.3 Renin, prorenin and renin-prorenin receptor 
Blockade of renin improves insulin sensitivity. In subjects with the metabolic syndrome 
treatment with a renin inhibitor improved insulin sensitivity, as compared to an ARB (193). 
In a rat model of RAAS activation, a renin inhibitor led to improved insulin resistance and 
signalling, and also improved glucose uptake in skeletal muscle (93).  Improvements in 
insulin signalling may also be due to decreased levels of Ang II and aldosterone, and this 
makes it hard to determine whether the effects of renin inhibition are through effects of renin 
blockade, or through the effects of decreasing downstream levels of Ang II or aldosterone. 
1.8 HAEMOSTASIS 
Haemostasis consists of the platelet system, the coagulation and the fibrinolytic system, and 
is often classified as: 
 Primary haemostasis:  
- Vascular contraction. 
- Platelet activation and aggregation. 
 Secondary haemostasis: 
- Coagulation. Consists of TF (extrinsic) and contact (intrinsic) pathways. 
- Fibrin formation and clot stabilitation. 
 Fibrinolysis: 
- Removing of the clot, once blood vessel integrity has been restored. 
Haemostasis is a fine-tuned balanced system, and in normal conditions the factors for 
haemostasis are present in inactivated forms in circulating blood and can typically be 
activated upon vessel inflammation or damage. During inflammatory states involving ED 
disturbances at several levels of the haemostatic system, this may result in pathophysiological 
changes in primary and secondary haemostasis or fibrinolysis. 
1.8.1 Coagulation  
The TF (extrinsic) and contact (intrinsic) pathways divide the coagulation cascade into two 
parts.  
1.8.1.1 Tissue factor pathway (extrinsic) 
The TF (or extrinsic) pathway, the major inducer of the coagulation cascade, is initiated when 
TF is bound to FVII-FVIIa (see figure 8). The TF-FVIIa complex cleaves FX into FXa, and 
FIX into FIXa, respectively. FXa then forms the prothrombinase complex when associated 
with FVa and Ca
2+
 on activated platelets, resulting in thrombin formation. The reaction is 
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much faster (300,000-fold than baseline) in the presence of negatively charged surface 
phospholipids (i.e. phoshatidylserine) on activated platelet membranes. Microparticles (MPs) 
may also accelerate thrombin generation due to a procoagulant phosphatidylserine-rich 
surface that supports thrombin generation (194). 
TF has for long been known to be present in the extravascular space (in subendothelial tissue) 
and not exposed to flowing blood, except during plaque rupture. TF is also present in 
circulating blood, mainly in three pools. The most important source of TF is monocytes, 
expressed as membrane-anchored and membrane-bound. There is no evidence that 
granulocytes express TF, rather they seem to acquire TF from monocytes (195). 
Controversial is the expression of TF in platelets. Platelets might store TF in α-granules or 
acquire TF from TF-containing MPs (196, 197). The second source of circulating TF is 
different cell-derived MPs, which are considered to be key players in atherothrombosis. The 
third pool, probably of minor importance, is a spliced form of TF, which is soluble and 
circulates in the blood (198). 
The importance of the intravascular blood-borne TF is controversial. Blood-borne TF means 
that the coagulation cascade may be activated without contact between the blood and the 
extravascular space (i.e. plaque rupture). This appears to be an important contribution in 
intravascular thrombosis (199).  
Blood-borne TF implicates that TF apparent on the surface of cells has a low activity, and 
under normal conditions TF is obviously in an inactive, cryptic, state. To be functionally 
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is formed to initiate the coagulation process. The amount of thrombin generated is 
under the influence of tissue factor pathway inhibitor (TFPI) activity as it rapidly 
inhibits FXa. 
 
 Amplification phase: This response takes place on phospholipid surfaces, mostly on 
activated platelets. The stimulus is amplified as platelets are activated and accumulate 
cofactors on their surfaces. Activated platelets release FV, which is activated by 
thrombin or FXa into FVa. Circulating vWF-FVIII complexes bind to activated platelets 
and FVIII is released and activated into FVIIIa by thrombin. 
 
 Propagation phase: Finally, the active proteases combine with their cofactors on 
phospholipid surfaces of activated platelets, but can also take place on MPs, activated 
ECs or VLDLs. The tenase complex, consisting of FIXa-FVIIIa and Ca2+
 
activates FX 
into FXa. Thereafter the prothrombinase complex, consisting of FXa-FVa and Ca2+, 
induces a thrombin burst that converts fibrinogen into fibrin. Thrombin activation of 
FXIII cross-links the fibrin monomers and stabilizes the platelet plug. Thrombin also 
stimulates on-going coagulation by feedback activation of FXIa.  
1.8.1.3 Contact pathway (intrinsic) 
Thrombin may also be activated by the contact (or intrinsic) pathway (see figure 8). The 
contact activation pathway is less prominent for haemostasis under healthy conditions than 
the TF pathway. However, states like hyperlipidaemia may lead to thrombosis via the contact 
pathway (206).  
The contact pathway consists of FVIII to FXII. Also required are prekallikrein and the 
cofactor high-molecular-weight kininogen, and calcium ions. The contact pathway requires a 
surface with negatively charged phospholipids, often secreted from platelets. Interaction with 
phospholipids may also occur on certain lipoproteins, such as chylomicrons, VLDLs or 
oxLDLs. Thus hyperlipidaemia can promote a prothrombotic state via the contact pathway.   
The contact phase is initiated as prekallikrein is converted to kallikrein, cleaving FXII to 
FXIIa. In turn, FXIIa then cleaves FXI to FXIa. FXIIa will also convert prekallikrein to 
kallikrein, through mutual activation. Kallikrein can acts upon kininogens that leads to the 
release of the vasodilator bradykinin. FXIa activates FIX to FIXa, in the presence of Ca
2+
. 
FIXa then cleaves FX to active FXa. Activation of FXa needs the tenase complex on platelets 
or certain lipoproteins. FVIII is mainly produced by the liver, and circulates in an inactive 
state in blood in complex with vWF. The activation of FVIII to FVIIIa occurs with minute 
quantities of thrombin or FXa. During activation FVIII dissociates from vWF and becomes 
fully activated and then participates in the FX activating complex. But when thrombin 
concentration increases, FVIIIa is inactivated by thrombin. Hence, thrombin has a dual action 
upon FVIII, and regulates the extent of the amount of the tenase complex formed and 
consequently has an important impact on the activity of the coagulation cascade (207, 208). 
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Figure 8. Blood coagulation cascade. To clarify the figure zymogens are not depicted. F, 
coagulation factor; Xa-Va, FXa-FVa complex or the prothrombinase complex; IXa-VIIIa, 
FIXa-FVIIIa complex or the tenase complex; IIa, FIIa or thrombin; XIIIa, FXIIIa; PC, protein 
C; APC, activated protein C; PS, protein S; TF-VIIa, tissue factor-FVIIa complex; AT, 
antithrombin; TM, thrombomodulin; t-PA, tissue plasminogen activator; TFPI, tissue factor 
pathway inhibitor; Xia, FXIa; TAFI, thrombin activatable fibrinolysis inhibitor; α2-AP, alpha 2-
antiplasmin; PAI, plasminogen activator inhibitor; FDP, fibrin degradation products and 
Ca2+, calcium ion. Figure modified from Bouma BN, 2006 (209). 
1.8.1.4 The role of thrombin 
Thrombin is of vital importance in the coagulation cascade. The main action is to act as a 
procoagulant by converting fibrinogen to fibrin monomers. Thrombin also exercises an 
anticoagulant role by binding to TM at the intact endothelium and to promote activation of 
the protein C (PC) pathway. APC then inactivates FVa and FVIIIa, two essential cofactors 
for FXa and FIXa, thereby down-regulating thrombin generation (210). Thrombin also has 
a central role in inflammatory response and stimulates different types of cells in the 
vasculature and in blood, including ECs, VSMCs and platelets. Effects of thrombin are 
mediated by their counter-receptors termed protease-activated receptors (PAR)s. PARs are 
G protein-coupled receptors, and four receptors have been identified (PAR 1-4), and PAR-1 
has been identified as the main thrombin receptor in vessels and on platelets. 
Thrombin signalling in platelets contributes significantly to haemostasis and thrombosis. It 
is the most effective platelet activator and causes the platelets to change shape and secrete 
adenosine diphosphate, serotonin, TXA2, chemokines, growth factors, mobilization of P-
selectin and CD40L, activation of αIIbβ3 and, ultimately, platelet aggregation (211). 
Platelets in humans express PAR-1 and PAR-4. PAR-1 seems to be the main platelet 
receptor for thrombin, and can activate platelets even at very low thrombin concentrations. 
Thrombin also promotes the release of EC MPs that seem to be critical in vascular 
pathophysiology (212). Once trace amounts of thrombin have been generated this is then 
able to activate FV, FVIII, FXI and FXIII. 
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In the healthy endothelium, thrombin activates PAR-1 and stimulates the production of 
prostacyclin and NO, leading to vasodilatation and activation of fibrinolysis by the release 
of t-PA (213). During inflammation and dysfunction of the endothelium PAR expression is 
increased in the endothelium, priming the response of ECs to thrombin and shifting ECs to 
a proinflammatory phenotype, inducing synthesis and release of PAI-1, contributing to 
impaired fibrinolysis (214). In pathophysiological conditions PAR-1 activation causes 
morphological changes, an increased vascular leakage and the release of proinflammatory 
cytokines, as well as up-regulation of adhesion molecules (215). In particular the synthesis 
of IL-6 seems to mediate the transition of the inflammatory process in the vessels from an 
acute to a chronic phase (216). Activation of PAR-1 also mobilizes p-selectin and vWF 
from Weibel-Palade bodies, promoting EC rolling and subsequently firm adhesion of both 
platelets and leukocytes.   
In healthy arteries PARs are preferably expressed in ECs, while their expression in VSMCs 
is limited. In hypertension and atherosclerotic vessels PAR-1 is up-regulated in VSMCs 
(214). This implies that PARs on VSMCs have a more prominent role under pathological 
conditions. In states associated with ED, PARs in VSMCs mediate contraction, 
proliferation, migration, hypertrophy and the production of ECM (214).   
Thrombin activatable fibrinolysis inhibitor (TAFI) originates from the liver, and is 
transported in the plasma as a zymogen, bound to plasminogen. The thrombin-TM complex 
activates TAFI preventing up-regulation of plasminogen binding and activation and reduces 
the binding of plasminogen, plasmin and t-PA to fibrin and thus slowing clot lysis (217). 
 
Figure 9. Role of thrombin in the coagulation system. ICAM, intracellular cell adhesion 
molecule; PAI, plasminogen activator inhibitor; vWF, von Willebrand factor; IL, interleukin; 
TAFI, thrombin fibrinolysis activatable inhibitor; TM, thrombomodulin; APC, activated 
protein C and F, coagulation factor. Figure modified from Davidson SJ, 2013 (218). 
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Altogether, in healthy conditions thrombin and PAR-1 activation causes endothelium 
dependent vasodilatation. On the other hand, in pathological conditions, thrombin regulates 
several components, which induces a procoagulatory and proinflammatory state (figure 9). 
1.8.2 Fibrinolysis 
The fibrinolytic system aims to dissolve and remove clots within the circulation. The 
zymogen plasminogen is released from the liver and is accumulated in fibrin-rich clots. Upon 
activation plasminogen is cleaved to plasmin by a variety of enzymes. The main regulator of 
fibrinolysis is t-PA released from ECs. In endotoxemia and cytokinemia the fibrinolytic 
system is transiently activated but thereafter depressed due to elevated PAI-1 levels. PAI-1 
appears in human blood in 3 different forms, active, latent (representing an inactive form) and 
complexed to t-PA or urokinase-PA. Concentration of PAI-1 exceeds t-PA by a 4:1 ratio and 
PAI-1 binding to t-PA or urokinase-PA occurs in a ratio of 1:1, thereby effectively limiting 
fibrinolysis. When PAI-1 levels are increased the t-PA half-life is considerably shortened, 
and a negative correlation is present between PAI-1 and plasmin-antiplasmin (PAP) 
complexes. The complex of t-PA/PAI-1 is stable, and eliminated from the circulation by the 
liver. PAI-1 half-life is around 2-4 h, and has a diurnal variation with a peak at 3 a.m. and 
falls during morning to a lowest level in the afternoon (219). TNF-α is important in the 
induction of the fibrinolytic responses, while IL-6 have been shown to be most relevant for 
coagulation activation (202), but also enzymes like kallikrein, FXIa and FXIIa may convert 
plasminogen into plasmin. Plasmin acts by degrading fibrin into d-dimers. The main inhibitor 
of fibrinolysis and t-PA is PAI-1, while α2-antiplasmin and α2-macroglobulin inhibits 
plasmin. 
1.8.3 Fibrinolysis and the RAAS 
The RAAS may influence the fibrinolytic system since Ang II have been reported to 
stimulate the production of PAI-1 by ECs and VSMCs, and bradykinin (which is degraded by 
the ACE) to stimulate the production of t-PA (220). Ang II can increase protein activity of TF 
and PAI-1 activities and the activities were increased already after 4 h (10). Ang II has also 
been observed to increase PAI-1 and t-PA activator messenger RNA in rat ECs and aortic 
VSMCs (221). Additional experiments have demonstrated that Ang IV caused an increased 
PAI-1 expression and the response exhibited a fast time and a dose dependence, while the 
induction of PAI-I messenger RNA expression produced by Ang II was evident within 1 h 
and is maximal at 4 h (222). Blocking the RAAS by ACE inhibition after myocardial 
infarction has been shown to improve the fibrinolytic balance (223). 
Ang II infusion also increases the expression of messenger RNA PAI-1 in the rat (224). In 
normotensive subjects and in hypertensive patients, Ang II infusion resulted in an increase in 
PAI-1 antigen, whereas no changes occurred regarding t-PA antigen (225). In conflict, Ang II 
did not involve any changes in PAI-1 antigen or activity in healthy subjects in other studies 
(226, 227). Thus, a link between PAI-1 and Ang II is at present unclear. 
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1.9 CROSSTALK BETWEEN INFLAMMATION AND COAGULATION  
Evidence suggests that inflammation and haemostasis are tightly interrelated and that these 
two systems affect each other in a bidirectional way, i.e. inflammation may lead to activation 
of the haemostatic system, while the haemostatic system has an impact on the inflammatory 
activity (228).  
Cross-talk between inflammation and haemostasis helps to explain prothrombotic states in 
inflammatory environments, such as the marked inflammatory response following cardiac 
surgery, when an uncontrolled inflammatory response leads to a profound disturbance in the 
coagulation system. In contrast, activated coagulation factors can directly stimulate an 
inflammatory response. In particular thrombin can activate receptors on mononuclear cells or 
ECs, which may induce cytokines and cause an inflammatory response. 
1.9.1 Inflammation induced coagulation activation 
Cytokines are responsible for inflammatory induced activation of haemostasis. A number of 
trials show the vital importance of the cytokine IL-6 in the activation of coagulation, and also 
important roles of IL-1, IL-8, TNF-α, and MCP-1 (201, 229). The inflammatory mediators 
trigger disturbance of the haemostatic system through different mechanisms: 
 Endothelial dysfunction 
 Activation of platelets 
 Activation of coagulation cascade through TF 
 Suppressed anticoagulant pathways 
 Impaired fibrinolytic activity 
1.9.1.1 Endothelial dysfunction 
Intact endothelium offers an anti-thrombotic surface, thereby preventing coagulation 
activation. Under healthy conditions ECs produce components with anti-inflammatory, 
anticoagulant and profibrinolytic properties, but in inflammatory conditions, ECs release 
procoagulant and anti-fibrinolytic mediators (like vWF, TXA2 and PAI-1). Activated ECs 
express TF and adhesion molecules, which are of vital importance in mediating the 
interaction of leukocytes and platelets with the ECs, and thus in activating the coagulant 
system and in promoting an inflammatory response. The cytokines IL-1, IL-6, IL-8, TNF-α 
and the chemokine MCP-1 have a key role in mediating the procoagulant changes in ED 
(201, 229).  
1.9.1.2 Activation of platelets 
In healthy conditions platelets circulate in a resting state. Intact ECs release NO and PGI2 to 
maintain disc-shape resting platelets. Several factors contribute to the activation of platelets. 
EC dysfunction activates platelets via the imbalance of increased production of vWF and 
TXA2 and the simultaneous decrease of NO and PGI2. Platelets can also be directly activated 
by endotoxins, cytokines such as IL-6 or PAF and VLDL (166, 230, 231). One of the 
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strongest platelet activator is thrombin, by binding on platelet receptors for thrombin (in 
particular PAR-1, but also PAR-4) (232).  
When activated, platelets undergo a substantial shape change, and immediately express at 
their surface or secrete, from alpha or dense granules, proinflammatory and procoagulant 
substances (39). Several hundreds of different platelet derived mediators have been identified. 
Activated platelets synthesize TXA2, while adenosine diphosphate and ATP are released 
from dense granules. These mediators amplify activation of platelets and recruit circulating 
platelets. Activated platelets also express receptors for β1 and β3 integrins, mediating platelet 
adhesion and aggregation.  
When platelets and ECs are activated, P-selectin is translocated to the cell surface where it 
functions as a PSGL-1 receptor, expressed on leukocytes (and in small amounts on platelets). 
The subsequent P-selectin and PSGL-1 interaction in turn increases the release of cytokines 
and chemokines from neutrophils and monocytes. The interaction also stimulates the up-
regulation of adhesion molecules and TF on ECs and leukocytes (233).  
IL-1β is a pivotal mediator in the cytokine cascade and also an important activator of ECs, by 
inducing the cytokines IL-6, IL-8 and chemokine MCP-1 (234). Platelet IL-1β also induces 
up-regulation of adhesion molecules like ICAM-1 and the vitronectin receptor (αvβ3), 
contributing to adhesion of neutrophils and monocytes to ECs (235).  
CD40L is also a key player in platelet activation. CD40L and its receptor CD40 are expressed 
in cells including platelets, ECs, VSMCs, T lymphocytes and macrophages (236). When 
activated, platelets rapidly (within seconds) express CD40L, and the interaction of CD40L 
and CD40 on ECs up-regulate the cytokines IL-8 and IL-6, MCP-1 and adhesion molecules, 
as well as increasing TF expression (237).  
Human platelets appear not to express TF when activated (238). On the other hand, activated 
platelets generate MPs that seem to express TF on their surface and contain negatively 
charged phospholipids, two factors of major importance for coagulation reactions (239). 
Figure 10 summarizes the most common proteins released upon platelet activation. 
1.9.1.3 Activation of coagulation cascade through TF 
The coagulation cascade in inflammatory states is mainly mediated by TF (240). Under 
physiological conditions TF is not expressed or is in an inactive state in circulatory cells or 
ECs. However, various inflammatory signals, like the cytokines IL-6, IL-1 or TNF-α, can 
induce TF activation in leukocytes (i.e. monocytes and macrophages) and ECs. Also CRP 
seems to have a role in coagulation as CRP can induce TF activation via a NF-κB pathway in 
both ECs and VSMCs (203).  Other mediators like oxLDL (241) and oxygen free radicals 
(242) can enhance TF activation. This enables active TF to be exposed to blood and bind to 
FVII. The complex of TF and FVIIa then contributes to the conversion of FIX and FX into 
the active proteases FXa and FXa, thereby generating thrombin. 
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Figure 10. Activation of platelets. MPs have negatively charged phospholipids on their 
surfaces and expresses TF. αIIbβ3, also known as glycoprotein IIbIIIa, the fibrinogen and 
vWF receptor; GPIbα-IX-V, the vWF receptor; αvβ3, the vitronectin receptor; α5β1, the 
fibronectin receptor; α6β1, the laminin receptor; α2β1 and GPVI are the receptors for 
collagen; GP, glycoprotein; β-TG, beta-thromboglobulin; PAF, platelet activating factor; CD, 
cluster of differentiation; MCP, monocyte chemoattractant protein; IL, interleukin; PF, platelet 
factor; RANTES, regulated on activation, normal T-cell expressed and secreted; NAP, 
neutrophil-activating peptide; LT, leukotriene; vWF, von Willebrand factor; F, coagulation 
factor; TFPI, tissue factor pathway inhibitor; PAI, plasminogen activator inhibitor; PDGF, 
platelet-derived growth factor; EGF, epidermal growth factor; VEGF, vascular endothelium 
growth factor; IGF, insulin growth factor; TGF-β, transforming growth factor beta and FGF, 
fibroblast growth factor. 
Under physiological circumstances, the presence of negatively charged membrane surfaces is 
limited, so even if activated coagulation factors are generated, the propagation of the 
coagulation cascade is limited. During inflammation activated platelets and ECs express 
negatively charged phospholipids on their surfaces, which is a prerequisite for assembly of 
activated coagulation factor complexes. 
1.9.1.4 Suppressed anticoagulant pathways 
The mechanisms that regulate coagulation activation are antithrombin (AT), the PC system 
and TFPI. The purpose of these systems is to prevent clotting of blood under healthy 
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conditions and also to dampen the activity of the coagulation system during vascular 
inflammation. Figure 8 summarizes the anticoagulant pathways. 
In addition to their effects on coagulation they also offer anti-inflammatory properties (243). 
The function of these pathways is impaired during inflammatory states and represents a 
mechanism in which inflammation leads to a procoagulant state (244).  
1.9.1.4.1 Antithrombin 
AT is produced by the liver and is the most important inhibitor of thrombin and FXa, but also 
FIXa, FXIa and FXIIa. Besides the anticoagulant properties AT seems to exert anti-
inflammatory properties. By binding of AT to thrombin, the levels of free, active thrombin is 
reduced, and this contributes per se to reduced activation of platelets, leukocytes and ECs. AT 
also seems to have direct interaction with leukocytes by blocking interaction with ECs, i.e. 
blocking leukocyte adhesion and migration on ECs (245).  
In inflammation, the AT pathway is impaired as a consequence of increased consumption, 
decreased synthesis in the liver and degradation by neutrophil elastase. Proinflammatory 
cytokines also cause reduced synthesis of GAGs, such as heparin sulphate, which may 
contribute to impaired AT function (246).  
1.9.1.4.2 Protein C system 
PC is a zymogen synthesized in the liver, and PC is activated when thrombin binds to TM, 
generating APC. This activation preferably occurs on the surface of intact endothelium. TM 
not only accelerates PC activation, by binding thrombin, but also directly impairs most of the 
procoagulant and proinflammatory effects of thrombin. The activation rate of PC is estimated 
to be increased 10-fold when it is adheres to the endothelial protein C receptor (EPCR) (247). 
APC binds reversibly to EPCR and must dissociate from the receptor before it can bind to its 
cofactor protein S (PS) to form the PS-APC complex that in turn inactivates FVa and FVIIIa. 
The PC system is the most complex anticoagulant pathway and appears to be the most 
important in affecting inflammation. It is considered that the APC-EPCR complex has anti-
inflammatory effects (248) by blocking the NF-κB translocation to the nucleus, resulting in 
decreased expression of cytokines and adhesion molecules in ECs and thereby inhibits the 
chemotaxis and adhesion of leukocytes to ECs. APC also stimulates fibrinolysis by forming a 
complex with PAI-1 and this reaction increases dramatically by vitronectin (249). TM has 
direct anti-inflammatory effects as TM inhibits leukocyte adhesion to the endothelium by 
attenuating the adhesion molecule expression via NF-κB and MAPK pathways (250). EPCR 
may be released as a circulating, soluble protein by IL-1, thrombin or inducible 
metalloproteinase in the ECs. This soluble EPCR then binds to a β2-integrin on neutrophils, 
and probably inhibits neutrophil trafficking (251). Additionally, the thrombin-TM complex 
activates TAFI, and thereby inhibits fibrinolysis. The function of the PC system is impaired 
during inflammatory states as both TM and EPCR have been shown to be down-regulated by 
inflammatory cytokines (252). Also, leukocyte activation and oxidant stress decrease the 
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activity of TM and neutrophil elastase may cleave TM rapidly, leading to a decreased PC 
activation (253) . 
1.9.1.4.3 Tissue factor pathway inhibitor 
TFPI can reversibly inhibit FXa, and the FXa-TFPI complex subsequently inhibits the FVIIa-
TF complex. Importantly, the complex of FXa-TFPI has been shown to be a more potent 
inhibitor of the FVIIa-TF than TFPI itself. TFPI is secreted by ECs and attached to the 
endothelium via GAGs. During inflammation and exposure of proinflammatory cytokines the 
synthesis of GAGs is reduced and this may affect the function of TFPI. Also ROS formation 
inhibits TFPI binding to FXa and loss of activity (254). 
1.9.1.5 Impaired fibrinolytic activity 
The fibrinolytic system controls haemostasis, and the pivotal enzyme, plasmin degrades the 
fibrin clot. The plasminogen activators generate plasmin from plasminogen. The major 
inhibitor of t-PA and urokinase-PA, is PAI-1. When PAI-1 binds to the plasminogen 
activators, inactivation of these plasminogen activators takes place, and consequently the 
activity of the fibrinolysis is supressed. 
The ratio between t-PA and PAI-1 modulates the fibrinolytic activity (255). The immediate 
response during inflammatory stimuli is a transient increase in the secretion of t-PA from 
Weibel-Palade bodies in ECs (256). This increase in the fibrinolytic activation is followed 
by a delayed suppression of the t-PA production and a sustained increase in PAI-1, 
resulting in a suppression of the fibrinolytic activity. The major regulators of PAI-1 activity 
at inflammatory sites seem to be cytokines, such as IL-6, IL-1β and TNF-α (219, 257). CRP 
has also been shown to stimulate the expression of PAI-1 (34). Alpha granules in platelets 
also contain PAI-1 that can be released upon activation, which increases PAI-1 and thereby 
contributes to suppression of fibrinolysis in inflammatory states. High levels of PAI-1 and t-
PA have been shown to predict development of a first cardiovascular event (258). 
1.9.2 Coagulation induced inflammatory activation via PARs 
Inflammation induces activation of the coagulation cascade, and the coagulation pathway 
triggers an intracellular inflammatory pathway. This cross-talk causes a positive feedback 
loop which amplifies an inflammation-thrombosis circuit (259).  
The coagulation factors can induce vascular inflammation by their binding to PARs (260). 
PARs are present in ECs, leukocytes, platelets, fibroblasts and VSMCs (260). An exceptional 
characteristic of PARs is that these receptors carry their own ligand, which is unmasked until 
the receptor is cleaved. Thrombin is known to be the most essential player in activation of 
PARs, and can activate PAR-1, PAR-3 as well as PAR-4. FXa transmits activation of PAR-1 
to PAR-3, while TF-FVIIa transmits activation of PAR-2 (260).  
PAR activation causes an up-regulation of inflammatory molecules, like cytokines, 
chemokines, growth factors and adhesion molecules. Experiments in healthy human subjects 
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have shown that recombinant FVIIa results in a 4-fold increase in the concentrations of IL-8 
and IL-6 in plasma (261). Activation of PARs transforms ECs into a proinflammatory 
phenotype, causing vascular permeability and local accumulation of platelets and leucocytes. 
In VSMCs, PAR activation mediates contraction, proliferation, migration, hypertrophy and 
modulation of the ECM, thereby contributing to atherosclerosis and hypertension. Platelets 
exhibit a pivotal role in the cross-talk between coagulation and inflammation, and are 
activated directly by thrombin or by proinflammatory mediators, such as PAF (230). The 
platelet P-selectins not only mediate adherence to leukocytes and ECs, but also enhance 
monocyte TF expression (262). Figure 11 summarizes PAR activation.  
 
 
Figure 11. PAR activation. Exposure of TF-bearing cells results in generation of thrombin. 
Activation of platelets plays a pivotal role. Binding of TF-FVIIa complex or thrombin to 
specific PARs may affect inflammation by inducing release of cytokines, which modulates 
coagulation and fibrinolysis. PAR, protease-activated receptors; IL, interleukin; TLR, Toll-like 
receptor; CD, cluster of differentiation; PF, platelet factor and RANTES, regulated on 
activation, normal T-cell expressed and secreted. Figure modified from Levi M, 2012 (263). 
 
 
 
  
 
35 
 
have shown that recombinant FVIIa results in a 4-fold increase in the concentrations of IL-8 
and IL-6 in plasma (261). Activation of PARs transforms ECs into a proinflammatory 
phenotype, causing vascular permeability and local accumulation of platelets and leucocytes. 
In VSMCs, PAR activation mediates contraction, proliferation, migration, hypertrophy and 
modulation of the ECM, thereby contributing to atherosclerosis and hypertension. Platelets 
exhibit a pivotal role in the cross-talk between coagulation and inflammation, and are 
activated directly by thrombin or by proinflammatory mediators, such as PAF (230). The 
platelet P-selectins not only mediate adherence to leukocytes and ECs, but also enhance 
monocyte TF expression (262). Figure 11 summarizes PAR activation.  
 
 
Figure 11. PAR activation. Exposure of TF-bearing cells results in generation of thrombin. 
Activation of platelets plays a pivotal role. Binding of TF-FVIIa complex or thrombin to 
specific PARs may affect inflammation by inducing release of cytokines, which modulates 
coagulation and fibrinolysis. PAR, protease-activated receptors; IL, interleukin; TLR, Toll-like 
receptor; CD, cluster of differentiation; PF, platelet factor and RANTES, regulated on 
activation, normal T-cell expressed and secreted. Figure modified from Levi M, 2012 (263). 
 
 
 
  
 36 
 
 
 
 
36 
 
 
 
 37 
 
2 AIMS 
Hypertension, FCHL and FH have an increased risk of CVD and premature death. Ang II is 
implicated in hypertension and promotes atherosclerosis, and patients with hyperlipidaemia 
may by more sensitive to the potential proinflammatory and procoagulatory effects of Ang II. 
Antihypertensive treatment may reduce thromboembolic events in hypertension. Thus, the 
overall aims were investigate the potential importance of Ang II for haemostatic and 
inflammatory alterations in hypertension and hyperlipidaemia. 
The specific aims of this project were as follows: 
 To investigate the effects of blocking the RAAS with an ACE inhibitor on blood 
coagulation in subjects with hypertension (paper I). 
 To clarify the impact of antihypertensive treatment by blocking the RAAS on 
inflammation and haemostasis beyond the effects of BP by comparing the effects of an 
ACE inhibitor to treatment with an alpha 1-adrenoceptor blocker in subjects with 
hypertension (paper II).   
 To investigate the potential proinflammatory and prothrombotic effects of short-term 
stimulation by circulating Ang II in healthy individuals (papers III-V). 
 To study the potential differences in the effects of circulating Ang II on inflammation and 
haemostasis in patients with FCHL and FH compared to healthy subjects (papers III-V). 
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3 MATERIALS AND METHODS 
3.1 PATIENTS AND HEALTHY CONTROLS 
None of the patients in paper I-V had any history or evidence of CVD, congestive heart 
failure, diabetes mellitus, atrial fibrillation/flutter, autoimmune disorder, liver or chronic 
kidney disease.   
3.1.1 Papers I and II 
3.1.1.1 Study population and procedures, paper I 
Subjects with hypertension were included if their diastolic BP was 95-115 mmHg without 
antihypertensive treatment the previous 4 weeks. Details about the study, presenting the 
result that ACE inhibitors reduced cardiac workload during stressful situations, have been 
presented previously (264). In brief, 6 women and 10 men with mean age 51 years and 
mean body mass index 26 kg/m
2
 (range 21-35 kg/m
2
) were included. During the study, 
medication that might affect the coagulation or BP was not allowed. The participants had 
stage I hypertension according to the WHO classification, with no signs of target organ 
damage or characteristics that could indicate secondary hypertension. The duration of the 
hypertension was on average 10 years (range 6-13 years).  
The participants were given 5 mg ramipril or placebo once daily, during 6 weeks, in a 
double-blind cross-over design. All participants then continued into an open treatment with 
ramipril during a 6-month period. During this phase, dose titration of ramipril was allowed 
once daily. The goal was to achieve a diastolic BP lower than 95 mmHg, and the mean dose 
of ramipril was finally 7.5 mg once daily. Testing in the laboratory was carried out at 3 
times; at 6 and 12 weeks, and after ramipril treatment at 6 months. The participants arrived 
to the laboratory at 12 AM. They were instructed to take their study medication at 08-09 
AM in order to reach an estimated peak plasma drug concentration during testing. They 
were instructed to avoid smoking and refrain from caffeine products during the morning.  
Blood was collected from antecubital veins into test tubes containing 0.13 mmol/L sodium 
citrate immediately before and after each mental stress test. The blood samples were then 
without delay centrifuged at 2000g for 20 minutes at 20°C, and stored at -80°C until 
analysis. 
3.1.1.2 The mental stress test 
In paper I patients underwent a mental stress test that was a modified video version of 
Stroop’s colour word conflict test during 20 minutes (264). During this test colour words 
were rapidly shown in incongruent colours, at the same time, a third incongruent colour word 
was presented orally. The participants were instructed to mark the colour on a protocol with 
randomly listed colour words and to ignore the other two conflicting information pieces. In 
this test a hemodynamic response will reach a steady state within 8-10 minutes and the 
responses are reproducible. After the mental stress test followed a strict 30 minutes of quiet 
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seated rest. Heart rate and BP were measured by a noninvasive technique (Dinamap Exercise 
Monitor (Critkon Inc., Tampa, FL).    
3.1.1.3 Study population and procedures, paper II 
Patients were included if their office systolic BP was >140 mm Hg and/or their diastolic BP 
was >90 mm Hg. They were randomized to double-blind treatment (stratified by sex) with 
ramipril 5 mg once daily or doxazosin 4 mg once daily for 2 weeks. During the initial 
phase, the dose was titrated to ramipril 10 mg or doxazosin 8 mg once daily. Thereafter the 
participants were treated during an additional 10 weeks. Prior treatment with RAAS 
blockade was not allowed. We ruled out secondary hypertension by routine biochemical 
and physical examinations. Patients with WHO stage III hypertension were not included.  
We randomized 71 patients (63 were previously never treated for hypertension). In all, 5 
women and 5 men discontinued due to reported side effects (8 on doxazosin and 2 on 
ramipril). One female patient in the ramipril group and one male patient in the doxazosin 
group were excluded because of difficulties to obtain blood samples. Thus, 59 patients, 
achieved the targeted 10 weeks of treatment with 8 mg doxazosin once daily or 10 mg 
ramipril once daily (table 3). 
Table 3. Patient characteristics and and demographic information in paper II. 
 ramipril doxazosin 
Male/female (n) 20/12 19/8 
Age (years)  54 ± 13 53 ± 11 
Smokers (n) 2 2 
Body mass index (kg/m2)  26 ± 4 27 ± 5 
Glucose (mmol/L)  5.2 ± 0.5 5.5 ± 0.4 
Office systolic BP (mm Hg) 155 ± 9 151 ± 8 
Office systolic BP (mm Hg) 93 ± 7 93 ± 10 
Creatinine (µmol/L) 75 ± 15 77 ± 12 
eGFR (mL/minute/1.73m2) 93 ± 15 92 ± 13 
Leucocyte count (109/L) 5.2 ± 1.4 5.0 ± 1.0 
Platelet count (109/L) 214 ± 43 219 ± 50 
Total cholesterol (mmol/L) 5.3 ± 0.8 5.5 ± 1.3 
HDL cholesterol (mmol/L) 1.3 ± 0.4 1.4 ± 0.4 
LDL cholesterol (mmol/L) 3.5 ± 0.8 3.5 ± 1.1 
Triglycerides (mmol/L) 1.1 ± 1.0 1.1 ± 0.8 
Data are presented as mean ± values SD. Blood samples were taken fasting. No 
significant differences existed between the ramipril and doxazosin groups. BP, blood 
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pressure values obtained in the office on inclusion; eGFR, estimated glomerular filtration 
rate, which was calculated using the chronic kidney disease epidemiology collaboration 
formula; HDL, high density lipoproteins; and LDL, low density lipoproteins  
After fasting overnight the participants arrived in the morning for the examinations at 
baseline and at week 12. The patients were asked to take their study medication 2 h before 
they arrived to the laboratory, to achieve peak plasma concentrations. They were instructed 
not to smoke and to refrain from caffeine-containing beverages, fruit juices or vitamin C 
during the morning, and to refrain from any other medication (including thrombocyte 
inhibitory drugs for 7 days and non-steroid anti-inflammatory drugs for 2 days) prior the 
examinations. Fasting blood samples were obtained by blood collection needles (Eclipse, 
21G x 1-1/4") after 20 minutes of supine rest into Vacutainer tubes (Becton Dickinson Co. 
Cedex, Meylan, France).  
3.1.2 Paper III-V 
3.1.2.1 Study population 
In paper III and IV, FCHL was thought to exist if the lipoprotein phenotypes IIa, IIb, or 
IV, according to the Fredrickson classification (22), were found in the family or in the 
patient at several different times. There were 5 patients on lipid lowering therapy with 
statins and 1 was on antihypertensive treatment with an ACE inhibitor (table 4). 
Table 4. Patient characteristics of participants in paper III and IV. 
 FCHL ControlFCHL 
Male/female (n) 11/5 9/7 
Age (years)  47 ± 6 45 ± 6 
Smokers (n) 5 2 
Body mass index (kg/m2)  27 ± 3* 25 ± 4 
Systolic blood pressure (mm Hg)  130 ± 13 123 ± 12 
Diastolic  blood pressure (mm Hg) 84 ± 8 81 ± 8 
Pulse pressure (mm Hg) 46 ± 13 42 ± 7 
Heart rate (beats per minute) 64 ± 9 58 ± 10 
Glucose (mmol/L) 5.2 ± 0.9 4.8 ± 0.4 
Total cholesterol (mmol/L) 8.4 ± 2.3**** 4.7 ± 0.6 
HDL cholesterol (mmol/L) 0.8 ± 0.2*** 1.3 ± 0.5 
LDL cholesterol (mmol/L) 3.4 ± 1.8 3.1 ± 0.6 
Triglycerides (mmol/L) 7.4 ± 5.7**** 0.8 ± 0.3 
Data are presented as mean ± values SD. Statistical evaluation was performed by 
Student’s t-test. Significant differences between FCHL and controlFCHL are denoted as; *P 
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< 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. FCHL, familial combined 
hyperlipidaemia. HDL and LDL, high and low density lipoproteins. 
In paper IV, we characterized the FCHL patients in paper III with respect to insulin 
resistance by HOMA-IR (calculated as fasting insulin in mU/L x glucose in mmol/L/22.5). 
Placebo experiments with saline infusion were added to verify the stability of the 
experimental design and to assess the potential influence of diurnal variations (table 5). 
Table 5. Patient characteristics in paper IV. 
 FCHL ControlFCHL Placebo 
 
 
 
 
 
Male/female (n) 11/5 9/7 4/4 
Insulin (mU/L) 10.0 (5.9-12.2)**** 3.6 (3.0-4.4) 3.9 (3.1-6.6) 
Glucose (mmol/L) 5.2 ± 0.9 4.8 ± 0.4 5.0 ± 0.3 
HOMA-IR 2.2 (1.3-3.0)**** 0.7 (0.6-0.9) 0.8 (0.6-1.4) 
 
 
 
 
Data are presented as mean values ± SD or as median and interquartile ranges. Statistical 
evaluation was performed by Student’s t-test or Mann-Whitney non-parametric test. 
Significant differences between FCHL and controlFCHL are denoted as; *P < 0.05, **P < 
0.01, ***P < 0.001, and ****P < 0.0001. FCHL, familial combined hyperlipidaemia and 
HOMA-IR, Homeostasis model assessment of insulin resistance. 
In paper V a diagnosis of FH was based on high total cholesterol and LDL cholesterol 
levels combined with either a family history of high levels of cholesterol of first degree 
relatives and/or early ischaemic heart disease, or tendon xanthomas at physical 
examination. There were12 FCHL patients treated with statins and 3 of them were also 
treated with the cholesterol uptake inhibitor ezetimibe (table 6). 
3.1.2.2 Healthy controls 
Age-matched healthy control subjects were recruited from the local area by advertisements 
and from hospital staff. 
In paper III and IV the healthy subjects (9 males and 7 females) had fasting plasma 
triglyceride levels less than 2.3 mmol/L and total cholesterol levels less than 6.0 mmol/L. 
Systolic and diastolic BPs were less than 130 and 80 mm Hg, respectively. All healthy 
controls were free of medicines, including oral contraceptives. 
In paper V the healthy subjects (8 males and 8 females) had fasting plasma triglyceride 
levels less than 1.6 mmol/L and total cholesterol levels less than 5.6 mmol/L. Systolic and 
diastolic BPs were less than 140 and 85 mm Hg, respectively. All healthy controls were 
free of medicines, including oral contraceptives.  
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Table 6. Patient characteristics in paper V. 
 FH ControlFH Placebo 
 
 
 
 
 
Male/female (n) 8/8 8/8 4/4 
Age (years) 43 ± 8 39 ± 10 40 ± 9 
Current/former smokers (n) 0/5 0/7 0/3 
Body mass index (kg/m2) 27 (24-29) 24 (21-27) 24 (22-26) 
Systolic BP (mmHg) 127 ± 14* 116 ± 12 116 ± 13 
Diastolic BP (mmHg) 75 ± 8 73 ± 8 69 ± 7 
Pulse pressure (mm Hg) 48 (44-64)** 42 (36-48) 41 (40-52) 
Heart rate (beats/minute) 64 ± 11 63 ± 13 56 ± 7 
Glucose (mmol/L) 5.0 ± 0.4 5.2 ± 0.4 5.0 ± 0.3 
Insulin (mU/L) 6.4 (5.2-7.6) 4.6 (2.8-6.6) 3.9 (3.1-6.6) 
HOMA-IR 1.5  (1.1-1.7) 1.0 (0.6-1.6) 0.8 (0.6-1.4) 
Total chol (mmol/L) 8.6 ± 1.8**** 4.4 ± 0.7 5.1 ± 0.6 
HDL chol (mmol/L) 1.0 ± 0.3 1.2 ± 0.4 1.3 ± 0.2 
Non-HDL chol (mmol/L) 7.5 ± 1.9**** 3.2 ± 0.8 3.9 ± 1.4 
LDL chol (mmol/L) 6.8 ± 1.8**** 2.8 ± 0.8 3.4 ± 1.1 
Triglycerides (mmol/L) 1.3 (0.9-1.8)*** 0.7 (0.5-1.0) 0.9 (0.6-1.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as mean values ± SD or as median and interquartile ranges. Statistical 
evaluation was performed by Student’s t-test or Mann-Whitney non-parametric test. 
Significant differences between FH and controlFH are denoted as; *P < 0.05, **P < 0.01, 
***P < 0.001, and ****P < 0.0001. BP, blood pressure; HOMA-IR, Homeostasis model 
assessment of insulin resistance; chol, cholesterol; HDL, High-density lipoprotein and LDL, 
low-density lipoprotein.   
3.1.2.3 Study procedures and blood sampling 
All participants on antihypertensive or lipid lowering therapy were instructed to quit their 
medication 4 weeks before the start of the study. The subjects were asked to avoid smoking 
on the day of the investigation and avoid taking non-steroid anti-inflammatory or aspirin 
drugs at least 7 days prior to the investigation. After an overnight fast, the participants 
arrived at the Cardiovascular Research Laboratory between 07.00 and 08.00 a.m. For the 
Ang II infusion, an indwelling catheter was applied in supine position in a vein of the left 
arm. Blood was collected by Vacutainer technique, using blood collection needles (Eclipse, 
21G x 1-1/4") inserted in a vein of the right arm. The participants rested in the supine 
position during 20-30 minutes before the investigations started. BP was measured using a 
mercury sphygmomanometer technique. BP values are presented as the calculated mean of 
two separate measurements, taken about one minute apart.  
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Blood samples were taken at baseline, at 1 and/or 3 h, and 1 h after the infusion of Ang II. 
Blood was collected into Vacutainer tubes (Becton Dickinson, Meylan, France) that 
contained EDTA or sodium citrate (3.8%), as appropriate. The blood samples were 
immediately centrifuged at 2000g, at 20°C for 20 minutes, and then separated and 
administered in aliquots (0.5 mL) and stored in -80°C until analysis.  
3.1.2.4 Ang II infusion 
In paper III and IV we used Ang II (Angiotensin amid, Apoteksbolaget, Umeå, Sweden) 
while we used Ang II acetate (Clinalfa basic, Bachem AG, Basel, Switzerland) in paper V.  
Ang II was dissolved in physiological saline. The starting dose was 2 ng/kg/minute and 
every 5 minutes the dose was incremented with 2 ng/kg/minute up to 10 ng/kg/minute. This 
dose was then maintained for 3 h. We have used the dose of 10 ng/kg/minute earlier (13) 
and this dose has been shown to increase plasma Ang II concentrations to about 50 pmol/L, 
which has been estimated to be equal to 5 to 10 times basal levels in healthy subjects (265). 
If mean arterial pressure levels increased from the levels before the infusion began by more 
than 25 mm Hg, the infusion rate was reduced in steps of 2 ng/kg/minute due to a decision 
from the Regional Ethics Committee. 
3.1.2.5 Placebo infusion  
In paper IV and V we added separate experiments with placebo infusion (physiological 
saline) in eight subjects (4 women) to check the stability of the experimental design and to 
assess the potential influence of diurnal variations. The placebo participants had fasting 
triglyceride levels less than 2.2 mmol/L and total cholesterol levels less than 7.1 mmol/L, 
respectively, and their systolic BP and diastolic BP levels were less than 120 and 80 mm 
Hg, respectively.  
3.2 METHODS 
3.2.1 Calibrated automated thrombogram 
In paper II and V thrombin generation potential was measured according to the method 
calibrated automated thrombogram (CAT), reported by Hemker et al., and in accordance to 
the manufacturer instructions  (Thrombinoscope BV, Maastricht, the Netherlands) (266). We 
used Thrombinoscope BV reagents.  
The reactions were carried out in 96-well microtiter plates (Immulon 2HB transparent U-
bottom from Thermo Electron, Denmark). Two wells were needed for each experiment, one 
well to measure thrombin generation of a plasma sample and another for calibration. Briefly, 
80 μl platelet-poor plasma was mixed with 20 μl of a platelet poor-plasma reagent containing 
TF and phospholipids reaching final concentrations of TF of 5 pM and phospholipids of 4 
μM. In addition, 80 μl of the same platelet-poor plasma reagent was mixed with a thrombin 
calibrator. To start the reactions in wells for calibration and measurement, a fluorogenic 
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substance, specifically cleaved by thrombin, was then added together with CaCl2 in Hepes 
buffer. 
The fluorescence was analysed every ½ minute during 1 h by a Fluoroscan Ascent 
fluorometer (Thermo Scientific Vanta, Finland). A commercial software by the 
manufacturer (Thrombinoscope version 2007) calculated and presented five variables 
(266):  
 Peak thrombin concentration. The peak concentration of thrombin generated  
 Endogenous thrombin potential. The area under the curve that corresponds to the total 
amount of thrombin generated over 1 h. 
 Lag-time. The time interval until the beginning of thrombin generation. Corresponds to 
the clotting time 
 Time to peak thrombin concentration. The time interval until the peak thrombin 
concentration. Takes into account the amplification and propagation phases 
 Time to tail. Time that elapsed until the end of the thrombin generation, i.e. inhibition 
of thrombin generation by various anticoagulants.  
 
Figure 12. The five variables calculated in calibrated automated thrombogram, ETP, 
endogenous thrombin potential and AUC, area under curve. 
For example, a hypocoagulability state is characterized by a prolonged lag-time, and 
reductions in both peak thrombin and endogenous thrombin potential. On the other hand, a 
hypercoagulability state is characterized by a reduced lag-time and increased peak thrombin 
and endogenous thrombin potential values. 
3.2.2 Other laboratory methods 
We used commercially kits and calibrators to analyse quantities of inflammatory and 
haemostatic markers.  
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3.2.2.1 Paper I 
Fibrinogen was measured by a polymerization time method. TAT complex was analysed by 
using an enzyme immunoassay (Enzygnost TAT Micro; Behringwerke AG, Marburg, 
Germany). FVII was detected by an amidolytic method measuring all FVII activity 
generated after thromboplastin activator addition to the test tubes. 
3.2.2.2 Paper 2 
TAT complex was determined by using an enzyme immunoassay (Enzygnost TAT Micro; 
Behringwerke AG, Marburg, Germany). PAI-1 activity was analysed by using an enzyme 
immunoassay (TriniLIZE PAI-1 activity, Tcoag Ireland Ltd., Ireland). T-PA antigen was 
determined by using assays from R&D Systems (Abingdon, UK). IL-6, IL-8, IL-6R, high 
sensitive (hs) CRP, TNF-α and MCP-1 were analysed by using assays from MesoScale 
Diagnostic (Human Cytokine Assay, Ultra-Sensitive Kit, MSD, Bethesda, USA). 
3.2.2.3 Paper III 
HsIL-6, TNF-α and t-PA/PAI-1 complexes were assessed by using assays from R&D 
Systems (Abingdon, UK). F1+2 and TAT complex concentrations were determined by 
using enzyme assays from Behring-Werke AG (Marburg, Germany). 
3.2.2.4 Paper IV 
PAI-1 activity was analysed by an assay from Hyphen BioMed (Neuville-sur-Oise, France). 
PAP complex was measured by a classical two-site ELISA (267).    
3.2.2.5 Paper V 
PAI-1 activity was analysed by using an assay from Hyphen BioMed (Neuville sur Oise, 
France). PAP complex was determined by a classical two-site ELISA (267). F1+2 
concentrations were analysed by using assays from Siemens Healthcare (Marburg, 
Germany). HsIL-6 was analysed by using assays from R&D Systems (Abingdon, UK). 
Fibrinogen levels were determined by means of a Fibri-Prest Automate method (von Clauss 
method) from Diagnostica Stago (Asneres, France). 
3.2.2.6 Routine analyses 
3.2.2.6.1 Paper II 
Leukocyte counts were analysed by using an automated blood cell counter (Technicon H1, 
Hematology System, Technicon Instruments Corp. Tarrytown, NY, USA). Plasma glucose 
was determined by an automated routine method (Synchron LX, Beckman Coulter, Inc., 
Fullerton, CA, USA). The cholesterol and triglyceride levels were analysed by standard 
enzymatic techniques (Boehringer-Mannheim, Mannheim, Germany). 
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3.2.2.6.2 Paper III 
Leukocyte counts were determined by using an automated blood cell counter (Technicon 
H1, Hematology System, Technicon Instruments Corp. Tarrytown, NY, USA). Plasma 
glucose was determined by an automated routine method (Synchron LX, Beckman Coulter, 
Inc., Fullerton, CA, USA). The various lipoprotein particles were analysed by precipitation 
and centrifugation steps. The cholesterol and triglyceride levels were analysed by standard 
enzymatic techniques (Boehringer-Mannheim, Mannheim, Germany). 
3.2.2.6.3 Paper IV 
HsCRP was determined by turbidimetry (Beckman Coulter, Fullerton, California, USA). 
Insulin levels were determined by an automated immunometric sandwich method (Modular 
E170; Roche Diagnostics GmbH, Mannheim, Germany) and detection with 
electrochemiluminescence immunoassay. Insulin resistance was assessed by the 
homeostasis model assessment of insulin resistance (HOMA-IR, by the formula; insulin in 
mU/L × glucose in mmol/L/22.5). 
3.2.2.6.4 Paper V 
Leukocyte counts and hsCRP count were analysed by using an automated blood cell 
counter (Technicon H1, Hematology System, Technicon Instruments Corp., Tarrytown, 
NY, USA. Insulin resistance was assessed by HOMA-IR. Plasma creatinine, glucose, 
cholesterol and triglyceride contents of the various lipoprotein fractions were assessed by 
automated standard methods. 
3.3 STATISTICAL ANALYSES 
Statistical calculations in papers I-V were performed using Statistica'99 software, version 
7.7, series: 1205 (Statsoft Inc., Tulsa, Oklahoma, USA). Normality was considered to be 
present if skewness was more than -1 and less than 1. Normally distributed data are 
presented as mean ± standard deviation (SD), whereas skewed data are presented as median 
values and interquartile ranges. Variables with skewed distribution were logarithmically 
transformed. A probability (P) less than 0.05 was considered statistically significant. 
3.3.1.1 Paper I 
We used non-parametric tests, by analysis of variance (ANOVA, Friedman test) with 
appropriate post hoc testing or by paired comparisons (Wilcoxon signed rank test), as 
appropriate. We estimated that the study, with 2 alpha 0.05, would require 15 participants 
to offer a power of 0.80 to detect a TAT complex difference of 0.4 µg/L by treatment, with 
a SD 0.5 µg/L. 
3.3.1.2 Paper II 
Graphing techniques were used to assess outliers. Extreme values were considered invalid if 
exceeding 2 SD beyond mean values for the given time and treatment group, as proposed by 
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Vaughan et al (91), also after logarithmic transformation. For TAT complex, extreme outlier 
values were present in 5/27 on doxazosin and in 4/32 on ramipril; these values were replaced 
by the mean for the given time and treatment group. As for the other markers of inflammation 
and coagulation, only single outliers were identified and excluded. Comparison between 
study groups and the effects of treatment were made by repeated measures multivariable 
analysis of variance (MANOVA), accounting for the potential confounding of smoking. 
Analysis of changes in TAT complex levels at baseline and after 3 months of treatment with 
ramipril and doxazosin were made by using non-parametric tests by paired comparisons 
(Wilcoxon signed rank test). Assuming 2 alpha 0.05 and a power of 0.80, we estimated a 
study population of 2 x 26 subjects in order to detect a 0.4 µg/L difference in TAT complex 
by treatment, with a SD 0.5 µg/L.   
3.3.1.3 Paper III-IV 
Changes within and between the groups at baseline were analysed by Student's t-test or 
Mann-Whitney non-parametric test, as appropriate. The responses of Ang II infusion on 
BP, heart rate, markers of inflammation and haemostasis were determined by repeated 
measures ANOVA. We estimated that these studies, with 2 alpha 0.05, would require 15 
subjects to have a power of 0.80 to detect a TAT complex difference of 0.4 µg/L by 
infusion of Ang II, with a SD 0.5 µg/L.  
3.3.1.4 Paper V 
Changes within and between groups at baseline were investigated by Student’s t-test or 
Mann-Whitney non-parametric test, as appropriate. The responses of Ang II infusion on 
BP, heart rate, inflammatory and haemostatic markers were analysed by repeated measures 
ANOVA. Post hoc calculation indicated that the study, with 2 alpha 0.05, would require 14 
subjects to have a power of 0.80 to detect a PAI-1 activity difference of 1.0 ng/mL by Ang 
II infusion, with a SD 1.3 ng/mL. 
3.4 ETHICAL CONSIDERATIONS 
The studies were performed in accordance with the Declaration of Helsinki (1989) of the 
World Medical Association. All studies were approved by the Regional Ethics Committee 
of Karolinska University Hospital in Stockholm. We received informed consent from all 
participants.
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4 RESULTS 
4.1 PAPER I 
4.1.1 Effects on blood pressure and heart rate  
The results are presented in table 7. Systolic and diastolic BPs were reduced by treatment 
with ramipril, no effects were observed on heart rate. Placebo during 6 weeks did not 
affect BP or heart rate (data not shown). Systolic BP and heart rate responses during 
mental stress were attenuated by ramipril, for details, see (264). 
Table 7. Effects of ramipril treatment at rest and during mental stress. 
   Placebo Ramipril, 6 w Ramipril, 6 m 
Blood pressure (mm Hg) and heart rate (beats per minute) at rest 
Systolic BP 154 (138-165) 146 (128-154)* 140 (131-165) 
Diastolic BP 106 (94-110) 98 (86-109)*** 94 (87-103)** 
Heart rate 71 (66-73) 72 (66-80) 73 (67-78) 
Data are presented as median values and interquartile ranges during rest and following 
20 minutes of mental stress (n=15-16). Statistical evaluation was made by using non-
parametric tests by paired comparisons (Wilcoxon signed rank test). Significant 
differences are given as; *P < 0.05, **P < 0.01, ***P < 0.001 compared to placebo. W, 
weeks; m, months and BP, blood pressure. 
4.1.2 Effects on coagulation 
The results are presented in table 8 and figure 13. Ramipril treatment reduced TAT 
complex after 6 weeks and 6 months, while ramipril tended to reduce fibrinogen levels at 
6 months (P=0.06). Ramipril did not affect Factor VII. 
Table 8. Effects of ramipril treatment at rest and during mental stress. 
   Placebo Ramipril, 6 w Ramipril, 6 m 
TAT complex (µg/L) 
Rest 2.30 (1.65-3.78) 2.00 (1.38-2.15)* 1.80 (1.62-1.98)* 
Stress 2.05 (1.30-2.80) 1.90 (1.50-2.55) 1.80 (1.60-2.55) 
Fibrinogen (g/L) 
Rest 3.20 (2.85-4.10) 2.95 (2.80-4.05) 3.00 (2.65-3.42) 
Stress 3.45 (3.00-4.10)Ϯ 3.50 (3.05-3.90)Ϯ 3.10 (2.80-3.35) 
Factor VII (mg/L) 
Rest 1.24 (1.08-1.34) 1.24 (1.02-1.48) 1.33 (1.07-1.46) 
Stress 1.17 (1.02-1.40) 1.25 (1.10-1.50) 1.14 (1.06-1.40) 
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Data are presented as median values and interquartile ranges during rest and following 
20 minutes of mental stress (n=15-16). Statistical evaluation was made by using non-
parametric tests, by ANOVA (Friedman’s test) or by paired comparisons (Wilcoxon 
signed rank test). Significant differences are given as; *P < 0.05 compared to placebo; 
ϮP < 0.05 compared to resting conditions. W, weeks; m, months and TAT, thrombin-
antithrombin. 
Mental stress did not affect TAT or Factor VII. Fibrinogen increased during stress 
following both placebo and ramipril treatment for 6 weeks, but no effects after 6 months 
of ramipril treatment.  
Figure 13 illustrates changes in TAT complex levels for placebo and after ramipril 
therapy during 6 weeks and 6 months. 
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Figure 13. TAT complex at rest and during placebo and during ramipril therapy for 6 
weeks and 6 months. Data are presented as median and interquartile ranges, n=15. 
Significant differences are given as; *P < 0.05, compared to placebo. 
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4.2 PAPER II 
4.2.1 Effects on blood pressure and heart rate 
The results are presented in table 9. Antihypertensive treatment reduced systolic and 
diastolic BP in both study groups.  
Table 9. Treatment effects on blood pressure and heart rate. 
 Ramipril Doxazosin MANOVA 
Systolic blood pressure (mm Hg) 
Baseline 155 ± 9 151 ± 8 P group=0.38 
12 weeks 135 ± 12 142 ± 12 P time<0.001 
Δ 0 to 12 weeks -19 ± 12 -11 ± 12 P group x time=0.23 
Diastolic blood pressure (mm Hg) 
Baseline 93 ± 7 93 ± 10 P group=0.88 
12 weeks 79 ± 6 83 ± 10 P time<0.001 
Δ 0 to 12 weeks -15 ± 8 -10 ± 7 P group x time=0.085 
Heart rate (beats per minute) 
Baseline 62 ± 8 59 ± 8 P group=0.65 
12 weeks 62 ± 7 59 ± 10 P time=0.74 
Δ 0 to 12 weeks 0 ± 5 0 ± 7 P group x time=0.98 
Data are given mean values ± SD for 27-32 participants in each treatment group at week 
0 or 12. Δ represents absolute changes by treatment given as mean values ± SD. 
4.2.2 Effects on inflammation 
The results are presented in table 10. Although antihypertensive treatment overall did not 
affect hsIL-6, there was a difference between treatment with ramipril (increase) and with 
doxazosin (decrease). There were no changes in the soluble receptor for IL-6, soluble IL-
6R, and there were no changes in for the other markers of inflammation, either in 
treatment with ramipril or doxazosin. 
Table 10. Treatment effects on inflammatory markers.  
  Week Ramipril Doxazosin ANOVA 
HsIL-6 (pg/mL) 
0 0.28 (0.21-0.38) 0.29 (0.20-0.39) P group=0.78 
12 0.37 (0.24-0.48) 0.26 (0.20-0.43) P time=0.37 
Δ 0 to 12 0.13 ± 0.27 -0.01 ± 0.21 P group x time=0.012 
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HsIL-6R (ng/mL) 
0 29.2 (24.0-36.4) 30.4 (23.9-37.1) P group=0.97 
12 30.0 (24.8-36.1) 29.6 (22.8-36.4) P time=0.58 
Δ 0 to 12 0.8 ± 8.4 -2.4 ± 8.6 P group x time=0.11 
IL-8 (pg/mL) 
0 1.89 (1.34-2.44) 1.78 (1.46-2.17) P group=0.13 
12 1.66 (1.33-2.02) 1.45 (1.17-1.82) P time=0.84 
Δ 0 to 12 -0.07 ± 0.90 -0.36 ± 0.69 P group x time=0.69 
TNF-α (pg/mL) 
0 1.00 (0.81-1.13) 0.96 (0.80-1.19) P group=0.41 
12 1.03 (0.81-1.16) 0.94 (0.82-1.10) P time=0.31 
Δ 0 to 12 0.01 ± 0.25 -0.05 ± 0.23 P group x time0.81 
MCP-1 (pg/mL) 
0 42.2 (36.6-48.1) 42.2 (33.8-51.2) P group=0.14 
12 41.2 (34.6-43.0) 42.3 (35.5-52-0) P time=0.50 
Δ 0 to 12 -0.1 ± 10.6 1.0 ± 9.3 P group x time=0.90 
HsCRP (mg/L) 
0 1.31 (0.65-2.11) 1.80 (1.20-3.04) P group=0.52 
12 1.35 (0.70-2.67) 1.38 (0.92-2.25) P time=0.12 
Δ 0 to 12 0.13 ± 1.70 0.02 ± 2.34 P group x time=0.11 
Data are given as median values and interquartile ranges for 26-32 participants in each 
treatment group at week 0 and 12. Δ represents absolute changes by treatment given as 
mean values ± SD. Hs, high sensitive; IL, interleukin; R, receptor; TNF-α, tumor necrosis 
factor-α; MCP-1, monocyte chemoattractant protein-1 and CRP, C-reactive protein. 
4.2.3 Effects on fibrinolysis 
The results are presented in table 11. There were no changes in PAI-1 activity by 
treatment. Concentrations of t-PA antigen increased by ramipril, while it decreased by 
doxazosin.  
Table 11. Treatment effects on fibrinolytic markers.  
  Week Ramipril Doxazosin ANOVA 
PAI-1 activity (IU/mL) 
0 4.6 (1.2-10.1) 7.1 (2.3-16.1) P group=0.54 
12 6.1 (3.0-17.4) 7.2 (2.9-15.1) P time=0.93 
Δ 0 to 12 5.3 ± 9.2 -3.2 ± 13.1 P group x time=0.89 
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12 1.03 (0.81-1.16) 0.94 (0.82-1.10) P time=0.31 
Δ 0 to 12 0.01 ± 0.25 -0.05 ± 0.23 P group x time0.81 
MCP-1 (pg/mL) 
0 42.2 (36.6-48.1) 42.2 (33.8-51.2) P group=0.14 
12 41.2 (34.6-43.0) 42.3 (35.5-52-0) P time=0.50 
Δ 0 to 12 -0.1 ± 10.6 1.0 ± 9.3 P group x time=0.90 
HsCRP (mg/L) 
0 1.31 (0.65-2.11) 1.80 (1.20-3.04) P group=0.52 
12 1.35 (0.70-2.67) 1.38 (0.92-2.25) P time=0.12 
Δ 0 to 12 0.13 ± 1.70 0.02 ± 2.34 P group x time=0.11 
Data are given as median values and interquartile ranges for 26-32 participants in each 
treatment group at week 0 and 12. Δ represents absolute changes by treatment given as 
mean values ± SD. Hs, high sensitive; IL, interleukin; R, receptor; TNF-α, tumor necrosis 
factor-α; MCP-1, monocyte chemoattractant protein-1 and CRP, C-reactive protein. 
4.2.3 Effects on fibrinolysis 
The results are presented in table 11. There were no changes in PAI-1 activity by 
treatment. Concentrations of t-PA antigen increased by ramipril, while it decreased by 
doxazosin.  
Table 11. Treatment effects on fibrinolytic markers.  
  Week Ramipril Doxazosin ANOVA 
PAI-1 activity (IU/mL) 
0 4.6 (1.2-10.1) 7.1 (2.3-16.1) P group=0.54 
12 6.1 (3.0-17.4) 7.2 (2.9-15.1) P time=0.93 
Δ 0 to 12 5.3 ± 9.2 -3.2 ± 13.1 P group x time=0.89 
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t-PA antigen (ng/mL) 
0 3.49 ± 1.18 3.80 ± 1.08 P group=0.94 
12 3.67 ± 1.30 3.38 ± 0.96 P time=0.38 
Δ 0 to 12 0.18 ± 0.55 -0.42 ± 0.62 P group x time=0.008 
Data are given as mean values ± SD or median values and interquartile ranges for 25-29 
participants in each treatment group at week 0 and 12. Δ represents absolute changes 
by treatment given as mean values ± SD. PAI, plasminogen activator inhibitor and t-PA, 
tissue plasminogen activator. 
4.2.4 Effects on coagulation 
The results are presented in figure 14 and table 12. TAT complex decreased by treatment, 
and this was dependent on a reduction in TAT complex in the ramipril group alone. There 
were no changes in the CAT data by treatment.   
Figure 14 illustrates the changes in TAT complex after 3 months of therapy with ramipril 
and doxazosin. 
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Figure 14. TAT complex levels at baseline and after 3 months of treatment with ramipril 
and doxazosin. Data are presented as median values and interquartile ranges, n=28 for 
the ramipril group and n=22 for the doxazosin group. Statistical evaluation was made by 
using non-parametric tests by paired comparisons (Wilcoxon signed rank test). 
Significant differences are given as; *P < 0.05. 
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Table 12. Treatment effects on markers of coagulation.  
  Week Ramipril Doxazosin MANOVA 
TAT complex (µg/L) 
0 3.17 (2.15-3.78) 2.61 (2.14-3.23) P group=0.14 
12 2.69 (2.14-3.00) 2.75 (2.03-3.29) P time=0,025 
Δ 0 to 12 -0.47 ± 1.21 -0.05 ± 0.73 P group x time=0.014 
CAT, peak thrombin (nM) 
0 321 51 322 46 P group=0.11 
12 313 61 337 29 P time=0.92 
Δ 0 to 12 -8 ± 71 15 ± 52 P group x time=0.45 
CAT, endogenous thrombin potential (nM x minutes) 
0 1938 ± 298 2071 ± 270 P group=0.12 
12 1975 ± 396 2068 ± 386 P time=0.93 
Δ 0 to 12 37 ± 380 -3 ± 323 P group x time=0.50 
CAT, lag-time (minutes) 
0 3.7 ± 0.9 3.8 ± 0.6 P group=0.68 
12 3.8 ± 0.8 3.5 ± 0.6 P time=0.27 
Δ 0 to 12 0.1 ± 1.1 -0.3 ± 0.7 P group x time=0.14 
CAT, time to peak (minutes) 
0 6.7 ± 1.4 6.9 ± 1.1 P group=0.26 
12 6.8 ± 1.2 6.6 ± 1.0 P time=0.53 
Δ 0 to 12 0.1 ± 1.6 -0.4 ± 1.3 P group x time=0.44 
Data are given as mean values ± SD or as median values and interquartile ranges for 
22-31 participants in each treatment group at week 0 or 12. Δ represents absolute 
changes by treatment given as mean values ± SD. TAT, thrombin-antithrombin and CAT, 
calibrated automated thrombogram. 
Changes in TAT by treatment did not relate significantly to changes in BP from baseline 
to week 12, i.e., r = -0.01 (p = 0.98) for systolic BP, r = -0.08 (p = 0.60) for diastolic BP 
and r = 0.04 (p = 0.76) for pulse pressure (n=50); similar relations were obtained when 
the two study groups were analysed separately.  
 
56 
Table 12. Treatment effects on markers of coagulation.  
  Week Ramipril Doxazosin MANOVA 
TAT complex (µg/L) 
0 3.17 (2.15-3.78) 2.61 (2.14-3.23) P group=0.14 
12 2.69 (2.14-3.00) 2.75 (2.03-3.29) P time=0,025 
Δ 0 to 12 -0.47 ± 1.21 -0.05 ± 0.73 P group x time=0.014 
CAT, peak thrombin (nM) 
0 321 51 322 46 P group=0.11 
12 313 61 337 29 P time=0.92 
Δ 0 to 12 -8 ± 71 15 ± 52 P group x time=0.45 
CAT, endogenous thrombin potential (nM x minutes) 
0 1938 ± 298 2071 ± 270 P group=0.12 
12 1975 ± 396 2068 ± 386 P time=0.93 
Δ 0 to 12 37 ± 380 -3 ± 323 P group x time=0.50 
CAT, lag-time (minutes) 
0 3.7 ± 0.9 3.8 ± 0.6 P group=0.68 
12 3.8 ± 0.8 3.5 ± 0.6 P time=0.27 
Δ 0 to 12 0.1 ± 1.1 -0.3 ± 0.7 P group x time=0.14 
CAT, time to peak (minutes) 
0 6.7 ± 1.4 6.9 ± 1.1 P group=0.26 
12 6.8 ± 1.2 6.6 ± 1.0 P time=0.53 
Δ 0 to 12 0.1 ± 1.6 -0.4 ± 1.3 P group x time=0.44 
Data are given as mean values ± SD or as median values and interquartile ranges for 
22-31 participants in each treatment group at week 0 or 12. Δ represents absolute 
changes by treatment given as mean values ± SD. TAT, thrombin-antithrombin and CAT, 
calibrated automated thrombogram. 
Changes in TAT by treatment did not relate significantly to changes in BP from baseline 
to week 12, i.e., r = -0.01 (p = 0.98) for systolic BP, r = -0.08 (p = 0.60) for diastolic BP 
and r = 0.04 (p = 0.76) for pulse pressure (n=50); similar relations were obtained when 
the two study groups were analysed separately.  
 57 
 
4.3 PAPER III-V 
4.3.1 Effects on blood pressure and heart rate 
4.3.1.1 Baseline 
The results are presented in tables 4 and 6. Papers III and IV: FCHL had similar BP and 
heart rate compared to controlFCHL. Paper V: In FH, systolic BP and pulse pressure were 
higher compared to controlFH (P < 0.05 and P < 0.01, respectively). 
4.3.1.2 Ang II infusion 
The results are presented in table 13 and 14. Ang II infusion caused a marked and rapid 
increase in BP in all groups. Paper III and IV: In FCHL, the systolic BP increase was 
greater compared to controlFCHL. The diastolic BP increased similarly in FCHL and 
controlFCHL. After the end of Ang II infusion, BP returned rapidly to baseline levels. The 
heart rate decreased in both groups and returned to baseline levels after the end of the 
infusion. The heart rate responses were similar in FCHL and controlFCHL.  
Table 13. Systolic and diastolic blood pressure and heart rate before, during and after 
angiotensin II infusion in FCHL and controlFCHL. 
   0 h 0.5 h 2.5 h +0.5 h ANOVA 
Systolic blood pressure (mm Hg) 
FCHL 130 ± 13 161 ± 19 160 ± 11 131 ± 13 P group=0.002 
ControlFCHL 123 ± 12 143 ± 10 142 ± 11 119 ± 11 P time<0.0001 
     P group x time=0.003 
Diastolic blood pressure  (mm Hg) 
FCHL 84 ± 8 103 ± 7 102 ± 9 82 ± 8 P group=0.028 
ControlFCHL 81 ± 8 96 ± 9 95 ± 8 76 ± 9 P time<0.0001 
     P group x time=0.136 
Heart rate (beat per minute) 
FCHL 64 ± 9 62 ± 7 61 ± 7 67 ± 10 P group=0.043 
ControlFCHL 58 ± 10 56 ± 8 56 ± 8 61 ± 9 P time<0.0001 
     P group x time=0.944 
 
 
 
Data are presented as mean values ± SD, n=16 for each group. Comparisons over time 
were evaluated by repeated measures ANOVA. FCHL, familial combined 
hyperlipidaemia. 
Paper V: In FH, systolic and diastolic BP increased during Ang II infusion, and the 
responses were similar in FH compared to controlFH. After the end of Ang II infusion, BP 
returned rapidly to baseline levels. The heart rate decreased in both groups, and returned 
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to baseline levels after the infusion. The heart rate responses were similar in FH and 
controlFH. 
Table 14. Systolic and diastolic blood pressure and heart rate before, during and after 
angiotensin II infusion in FH, controlFH and saline (placebo). 
   0 h 0.3 h 3 h +0.3 h ANOVA 
Systolic blood pressure (mm Hg) 
FH 127 ± 14 152 ± 18 152 ± 13 127 ± 14 P group<0.01 
ControlFH 116 ± 12* 139 ± 16 138 ± 14 117 ± 10 P time<0.0001 
     P group x time=0.78 
Placebo 112 ± 9 107 ± 11 111 ± 10 111 ± 8 P time=0.60 
Diastolic blood pressure (mm Hg) 
FH 74 ± 8 99 ± 7 93 ± 8 77 ± 10 P group=0.11 
ControlFH 73 ± 8 90 ± 11 88 ± 10 70 ± 10 P time<0.0001 
     P group x time=0.10 
Placebo 69 ± 7 71 ± 12 73 ± 13 69 ± 7 P time=0.70 
Heart rate (beat per minute) 
FH 64 ± 11 61 ± 14 62 ± 11 66 ± 11 P group=0.75 
ControlFH 63 ± 13 59 ± 12 60 ± 11 67 ± 11 P time<0.0001 
     P group x time=0.39 
Placebo 56 ± 7 56 ± 5 57 ± 7 59 ± 7 P time=0.60 
Data are presented as mean values ± SD, n=16 for FH and for controlFH and n=8 for 
placebo. At baseline, statistical evaluation was performed by Student’s t-test. Significant 
differences are given as; *P < 0.05. Comparisons over time were evaluated by repeated 
measures ANOVA. FH, familial hypercholesterolemia. 
Due to a limitation from the Regional Ethics Committee, the mean arterial pressure was 
not allowed to increase by more than 25 mm Hg. Therefore, the Ang II infusion rate was 
reduced in 6 FCHL and in 2 controlFCHL , and the maintenance dose of Ang II was lower 
in FCHL, as compared to controlFCHL (9.1±1.0 vs. 9.8±0.7 ng/kg/minute, P < 0.05) 
(paper III and IV). In paper V, Ang II infusion rate was reduced in 7 FH and in 3 
controlFH. The maintenance doses of Ang II were similar in both FH and controlFH 
(7.5±2.8 vs. 8.7±2.3 ng/kg/minute, P=0.18). 
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4.3.2 Effects on inflammation 
4.3.2.1 Baseline 
The results are presented in table 15. Paper III and IV: FCHL had higher levels of IL-6 
(P < 0.05), leukocyte counts (P < 0.001) and hsCRP (P < 0.05) as compared to 
controlFCHL, while TNF-α was on the same levels in both groups. Paper V: FH had the 
same levels of IL-6, leukocyte counts, TNF-α and hsCRP compared to controlFH. 
However, the fibrinogen level was higher in FH (P < 0.05) compared to controlFH. 
Table 15. Markers of Inflammation before, during and after angiotensin II infusion in FCHL, 
controlFCHL, FH, controlFH and saline (placebo). 
   0 h 3 h +1 h ANOVA 
HsIL-6 (pg/mL) 
FCHL 1.1(1.0-1.8) 2.3(1.6-2.7) 2.9(1.9-3.6) P group=0.035 
ControlFCHL 0.7(0.5-1.2)* 1.5(1.1-2.1) 2.4(1.5-3.4) P time<0.0001 
    P group x time=0.19 
FH 0.4(0.4-0.9) 1.1(0.8-1.5) 2.0(0.8-4.3) P group=0.21 
ControlFH 0.6(0.3-1.0) 1.9(0.9-2.8) 2.5(1.5-4.1) P time<0.0001 
    P group x time=0.60 
Placebo 0.8(0.7-1.4) 1.0(0.6-2.3) 1.2(0.7-2.6) P time=0.10 
Leukocyte count (x 109) 
FCHL 5.9(5.5-6.9) 6.4(5.9-8.0) 6.1(5.6-7.3) P group=0.004 
ControlFCHL 4.6(3.9-5.5)*** 5.5(4.3-7.3) 5.4(4.1-6.6) P time<0.0001 
    P group x time=0.03 
FH 5.2 ± 1.2 5.7 ± 1.4 5.8 ± 1.5 P group=0.38 
ControlFH 5.6 ± 1.3 6.4 ± 1.7 6.1 ± 1.6 P time<0.0001 
    P group x time=0.30 
Placebo 5.5 ± 0.6 5.6 ± 0.8 5.8 ± 1.1 P time=0.47 
TNF-α (pg/mL) 
FCHL 1.0 ± 0.3 1.1 ± 0.2 1.1 ± 0.2 P group=0.90 
ControlFCHL 1.0 ± 0.4 1.0 ± 0.3 1.1 ± 0.3 P time=0.17 
    P group x time=0.42 
HsCRP (mg/L) 
FCHL 1.7(0.8-3.6) 
 
ControlFCHL 0.6(0.3-2.1)* 
FH 1.5(0.9-2.8) 
ControlFH 0.5(0.2-2.0) 
Placebo 0.6(0.3-1.3) 
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Fibrinogen (g/L) 
FH 2.7(2.2-3.1) 3.0(2.4-3.2)  P group=0.004 
ControlFH 2.1(2.0-2.4)* 2.2(2.0-2.4)  P time=0.005 
    P group x time=0.68 
Placebo 2.1(1.9-2.3) 1.9(1.9-2.5)  P time=0.67 
Data are presented as mean values ± SD or as median values and interquartile ranges. 
At baseline, statistical evaluation was performed by Student’s t-test or Mann-Whitney 
non-parametric test. Significant differences are given as; *P < 0.05, **P < 0.01 or ***P < 
0.001. Comparisons over time were evaluated by repeated measures ANOVA. FCHL, 
familial combined hypercholesterolemia and FH, familial hypercholesterolemia. 
4.3.2.2 Ang II infusion 
The results are presented in table 15 and figure 15. Paper III-V: Ang II infusion caused a 
similar increase in IL-6 in all four groups. The leukocyte count increased in a similar 
manner in all four groups during Ang II infusion. TNF-α did not change either in FCHL 
or controlFCHL. Fibrinogen increased in controlFH (P time < 0.05) and tended to increase 
in FH (P time=0.07). We could not observe any changes in placebo.  
Figure 15 illustrates the changes in IL-6 in all groups during Ang II infusion. 
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Figure 15. IL-6 in plasma before, during and after angiotensin II infusion. Data are 
presented as median values and interquartile ranges. PAI-1, plasminogen activator 
inhibitor-1; FCHL, familial combined hyperlipidaemia and FH, familial 
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hypercholesterolemia. FCHL, □; controlFCHL, 
 ■; FH, ○ and controlFH, ●. The effect of 
physiological saline infusion in placebo (Δ) is also shown.  
4.3.3 Effects on fibrinolysis 
4.3.3.1 Baseline 
The results are presented in table 16. Paper III and IV: FCHL had 3-fold higher levels of 
both t-PA/PAI-1 complexes and PAI-1 activity compared to controlFCHL (both P < 0.001). 
Also PAP complex were higher in FCHL compared to controlFCHL (P < 0.001). Paper V: 
In FH, PAI-1 activity and PAP complex levels were similar to controlFH. 
Table 16. Markers of fibrinolysis before, during and after angiotensin II infusion in FCHL, 
controlFCHL, FH, controlFH and saline (placebo). 
   0 h 1h 3 h +1 h ANOVA 
PAI-1 activity (ng/mL) 
FCHL 3.4 (1.0-7.0) 2.3 (0.8-5.9) 1.0 (0.3-2.3) 0.9 (0.3-1.8) P group<0.0001 
ContrFCHL 0.6 (0.2-1.1)*** 0.5 (0.2-0.8) 0.2 (0.1-0.3) 0.2 (0.1-0.3) P time<0.0001 
     P g x t=0.07 
FH 1.1 (0.6-1.7) 0.5 (0.3-1.3) 0.2 (0.1-0.5) 0.2 (0.1-0.6) P group=0.44 
ContrFH 0.9 (0.5-2.9) 0.6 (0.4-1.5) 0.4 (0.2-0.6) 0.3 (0.3-0.5) P time<0.0001 
     P g x t=0.64 
Placebo 0.7 (0.5-1.7) 0.4 (0.3-1.1) 0.3 (0.2-0.5) 0.2 (0.1-0.2) P time<0.0001 
PAP complex (µg/mL) 
FCHL 157 ± 37 147 ± 34 146 ± 32 146 ± 29 P group<0.001 
ContrFCHL 103 ± 8*** 105 ± 8 112 ± 12 127 ± 26 P time=0.08 
     P g x t<0.001 
FH 99 ± 13 95 ± 14 106 ± 14 109 ± 15 P group=0.99 
ContrFH 94 ± 27 96 ± 27 110 ± 44 109 ± 41 P time<0.0001 
     P g x t=0.57 
Placebo 83 ± 23 85 ± 20 88 ± 13 92 ± 20 P time=0.21  
t-PA/PAI-1 complex (ng/mL) 
FCHL 3.0 ± 0.8 2.7 ± 0.7 2.6 ± 0.8 2.6 ± 0.8 P group<0.0001 
ContrFCHL 1.0 ± 0.8*** 1.0 ± 0.7 0.9 ± 0.7 0.7 ± 0.6 P time<0.0001 
     P g x t=0.07 
Data are presented as mean values ± SD or as median values and interquartile ranges. 
At baseline, statistical evaluation was performed by Student’s t-test or Mann-Whitney 
non-parametric test. Significant differences are given as; *P < 0.05, **P < 0.01 or ***P < 
0.001. Comparisons over time were evaluated by repeated measures ANOVA. FCHL, 
familial combined hypercholesterolemia; FH, familial hypercholesterolemia; ContrFCHL, 
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control FCHL; ContrFH, control FH; t-PA, tissue plasminogen activator; PAI-1, 
plasminogen activator inhibitor-1 and PAP, plasmin-antiplasmin. 
4.3.3.2 Ang II infusion 
The results are presented in table 16 and figures 16-18. Paper III and IV: FCHL and 
controlFCHL had similar decreases in t-PA/PAI-1 complex (both P time < 0.0001) and 
PAI-1 activity (both P time < 0.0001) during Ang II infusion. PAP complex levels 
remained unchanged in FCHL during infusion of Ang II (P time=0.36) and during 
physiological saline infusion (P time=0.21). PAP complex levels increased in controlFCHL 
stimulation by during Ang II (P time < 0.0001). Paper V: In FH and controlFH we 
observed a decrease in PAI-1 activity (both, P time < 0.0001) and an increase in PAP 
complex (both, P time < 0.0001) during Ang II infusion. During saline infusion caused a 
decrease in PAI-1 activity (P time < 0.0001), reflecting a diurnal variation in fibrinolysis.  
Figure 16 and 17 illustrates the changes in PAI-1 activity and PAP complex in FCHL, 
controlFCHL, FH, controlFH and placebo during Ang II infusion, and figure 18 illustrates the 
changes in t-PA/PAI-1 complex in FCHL and controlFCHL during Ang II infusion. 
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Figure 16. PAI-1 activity in plasma before, during and after angiotensin II infusion. Data 
are presented as median values and interquartile ranges. PAI-1, plasminogen activator 
inhibitor-1; FCHL, familial combined hyperlipidaemia; FH, familial hypercholesterolemia. 
FCHL, □; controlFCHL, ■; FH, ○ and controlFH, ●. The effect of physiological saline infusion 
in placebo experiments (Δ) is also shown. 
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Figure 16. PAI-1 activity in plasma before, during and after angiotensin II infusion. Data 
are presented as median values and interquartile ranges. PAI-1, plasminogen activator 
inhibitor-1; FCHL, familial combined hyperlipidaemia; FH, familial hypercholesterolemia. 
FCHL, □; controlFCHL, ■; FH, ○ and controlFH, ●. The effect of physiological saline infusion 
in placebo experiments (Δ) is also shown. 
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Figure 17. PAP complex in plasma before, during and after angiotensin II infusion. Data 
are presented as mean values ± SD. PAP, plasmin-antiplasmin; FCHL, familial 
combined hyperlipidaemia and FH, familial hypercholesterolemia. FCHL, □; controlFCHL,
 
■; FH, ○ and controlFH,
 ●. The effect of physiological saline infusion in placebo 
experiments (Δ) is also shown. 
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Figure 17. PAP complex in plasma before, during and after angiotensin II infusion. Data 
are presented as mean values ± SD. PAP, plasmin-antiplasmin; FCHL, familial 
combined hyperlipidaemia and FH, familial hypercholesterolemia. FCHL, □; controlFCHL,
 
■; FH, ○ and controlFH,
 ●. The effect of physiological saline infusion in placebo 
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Figure 18. T-PA/PAI complex in plasma before, during and after angiotensin II infusion. 
Data are presented as mean values ± SD. T-PA, tissue plasminogen activator; PAP, 
plasmin-antiplasmin and FCHL, familial combined hyperlipidaemia. FCHL, □ and 
controlFCHL, ■.  
4.3.4 Effects on coagulation 
4.3.4.1 Baseline 
The results are presented in table 17. Paper III: FCHL and controlFCHL had the same 
concentrations of F1+2 and TAT complexes. Paper V: FH and controlFH had the same 
F1+2 levels. 
Table 17. Coagulation markers before, during, and after angiotensin II infusion in FCHL, 
controlFCHL, FH, controlFH and saline (placebo). 
   0 h 1 h 3 h +1 h ANOVA 
TAT complex (µg/L) 
(µg/mL) FCHL 1.5 (1.3-1.8) 1.8 (1.6-2.5) 2.3 (1.8-3.0) 2.1 (1.5-4.2) P group=0.94 
CFCHL 1.7 (1.6-2.6) 1.8 (1.4-2.3) 2.5 (1.6-3.1) 1.7 (1.4-3.4) P time=0.14 
        P g x t=0.62 
FCHL 1.5 (1.3-1.8) 1.8 (1.6-2.5) 2.3 (1.8-3.0)  P group=0.77 
CFCHL 1.7 (1.6-2.6) 1.8 (1.4-2.3) 2.5 (1.6-3.1)  P time=0.03 
     P g x t=0.38 
F1+2 (pmol/mL)  
FCHL 135 ± 36  134 ± 44 130 ± 37 P group=0.20 
CFCHL 122 ± 29  121 ± 36 110 ± 31 P time=0.09 
     P g x t=0.69 
FH 189 (152-229) 174 (139-201) 183 (139-216) 197 (137-222) P group=0.14 
CFH 157 (130-226) 169 (97-196) 144 (112-192) 162 (105-187) P time=0.29 
     P g x t=0.96 
Placebo 148 (135-167) 119 (118-133) 122 (112-133) 111 (105-132) P time<0.05 
Data are presented as mean values ± SD or as median values and interquartile ranges. 
At baseline, statistical evaluation was performed by Student’s t-test or Mann-Whitney 
non-parametric test. Comparisons over time were evaluated by repeated measures 
ANOVA. FCHL, familial combined hypercholesterolemia; FH; familial 
hypercholesterolemia; CFCHL, control FCHL and CFH, control FH. 
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Figure 18. T-PA/PAI complex in plasma before, during and after angiotensin II infusion. 
Data are presented as mean values ± SD. T-PA, tissue plasminogen activator; PAP, 
plasmin-antiplasmin and FCHL, familial combined hyperlipidaemia. FCHL, □ and 
controlFCHL, ■.  
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concentrations of F1+2 and TAT complexes. Paper V: FH and controlFH had the same 
F1+2 levels. 
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controlFCHL, FH, controlFH and saline (placebo). 
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TAT complex (µg/L) 
(µg/mL) FCHL 1.5 (1.3-1.8) 1.8 (1.6-2.5) 2.3 (1.8-3.0) 2.1 (1.5-4.2) P group=0.94 
CFCHL 1.7 (1.6-2.6) 1.8 (1.4-2.3) 2.5 (1.6-3.1) 1.7 (1.4-3.4) P time=0.14 
        P g x t=0.62 
FCHL 1.5 (1.3-1.8) 1.8 (1.6-2.5) 2.3 (1.8-3.0)  P group=0.77 
CFCHL 1.7 (1.6-2.6) 1.8 (1.4-2.3) 2.5 (1.6-3.1)  P time=0.03 
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F1+2 (pmol/mL)  
FCHL 135 ± 36  134 ± 44 130 ± 37 P group=0.20 
CFCHL 122 ± 29  121 ± 36 110 ± 31 P time=0.09 
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FH 189 (152-229) 174 (139-201) 183 (139-216) 197 (137-222) P group=0.14 
CFH 157 (130-226) 169 (97-196) 144 (112-192) 162 (105-187) P time=0.29 
     P g x t=0.96 
Placebo 148 (135-167) 119 (118-133) 122 (112-133) 111 (105-132) P time<0.05 
Data are presented as mean values ± SD or as median values and interquartile ranges. 
At baseline, statistical evaluation was performed by Student’s t-test or Mann-Whitney 
non-parametric test. Comparisons over time were evaluated by repeated measures 
ANOVA. FCHL, familial combined hypercholesterolemia; FH; familial 
hypercholesterolemia; CFCHL, control FCHL and CFH, control FH. 
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4.3.4.2 Ang II infusion 
The results are presented in table 17 and figure 19. Paper III: FCHL and controlFCHL had 
similar, not significant, increases in TAT complex during Ang II infusion when analysing 
the response in TAT complex during the infusion time, and including 1 h after the end of 
the infusion. On the other hand, if we analyse TAT complex during the ongoing infusion 
(0 h to 3 h), we instead get a significant increase in TAT complex, similar in FCHL and 
controlFCHL. Paper III-V: F1+2 did not change in FCHL, controlFCHL, FH or controlFH 
during Ang II infusion. In placebo, we observed a decrease in F1+2 during saline 
infusion.  
Figure 19 illustrates the changes in TAT complex in FCHL and controlFCHL during the 
ongoing Ang II infusion. 
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Figure 19. TAT complex in plasma before and during the ongoing angiotensin II infusion. 
Data are presented as median values and interquartile ranges. TAT, thrombin-
antithrombin and FCHL, familial combined hyperlipidaemia. FCHL, □ and controlFCHL,
 ■.  
4.3.4.3 Calibrated automated thrombogram 
4.3.4.3.1 Baseline 
The results are presented in table 18. Paper V: In FH subjects, we observed a higher peak 
concentration of thrombin generated and a higher endogenous thrombin potential (i.e. total 
amount of thrombin generated) compared to findings from controlFH.  FH and controlFH 
had similar time dependent parameters of thrombin generation; lag-time, time to peak 
thrombin and time to tail. 
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Figure 19. TAT complex in plasma before and during the ongoing angiotensin II infusion. 
Data are presented as median values and interquartile ranges. TAT, thrombin-
antithrombin and FCHL, familial combined hyperlipidaemia. FCHL, □ and controlFCHL,
 ■.  
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thrombin and time to tail. 
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Table 18. Calibrated automated thrombogram parameters before, during and after 
angiotensin II infusion in FH, controlFH and saline (placebo). 
 0 h 1 h 3 h +1 h ANOVA 
Peak thrombin (nM) 
FH 367 ± 47 367 ± 61 368 ± 56 364 ± 64 P group<0.05 
CFH 311 ± 57** 304 ± 65 303 ± 68 312 ± 56 P time=0.73 
 P g x t=0.89 
Pbo 325 ± 40 318 ± 43 314 ± 38 306 ± 48 P time=0.59 
 
 
Endogenous thrombin potential (nM x minutes) 
FH 2452 (2065-2768) 2494 (2264-2771) 2478 (2241-2813) 2423 (2151-2790) P group<0.05 
CFH 2000 (1821-2194)** 2019 (1776-2176) 1981 (1747-2240) 2028 (1761-2104) P time=0.08 
     P g x t=0.73 
Pbo 2011 (1878-2034) 1957 (1880-2230) 1890 (1867-2312) 1838 (1738-2233) P time=0.37 
Lag-time (minutes) 
FH 3.7 ± 0.4 3.8 ± 0.5 3.9 ± 0.4 3.8 ± 0.4 P group=0.08 
CFH 3.4 ± 0.6 3.5 ± 0.7 3.5 ± 0.7 3.5 ± 0.6 P time<0.001 
     P g x t=0.38 
Pbo 4.0 ± 0.6 4.1 ± 0.6 4.1 ± 0.6 4.2 ± 0.6 P time=0.16 
Time to peak thrombin (minutes) 
FH 6.5 (6.2-7.3) 6.8 (6.2-7.6) 6.8 (6.5-7.7) 6.9 (6.4-7.4) P group=0.33 
CFH   6.6 (5.7-7.0) 6.6 (6.0-7.2) 6.6 (6.0-7.3) 6.5 (5.7-6.9) P time<0.01 
     P g x t=0.28 
Pbo 6.8 (6.6-8.2) 7.0 (6.5-8.3) 7.0 (6.3-8.1) 6.7 (6.5-8.1) P time=0.69 
Time to tail (minutes) 
FH 26.5 (24.5-29.8) 27.0 (25.2-30.4) 27.7 (25.0-31.0) 27.5 (25.3-30.0) P group=0.22 
CFH 25.8 (23.2-27.2) 24.0 (23.1-29.0) 25.0 (24.0-29.0) 24.1 (22.2-28.5) P time=0.10 
     P g x t=0.46 
Pbo 25.0 (23.5-27.5) 25.0 (24.5-27.5) 25.9 (24.5-27.5) 24.0 (23.7-26.5) P time=0.50 
FH: Familial hypercholesterolemia. Data are presented as mean values ± SD or median 
values and interquartile ranges; n=16 for each FH and controlFH, and n=8 for placebo. At 
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baseline, statistical evaluation was performed by Student’s t-test or Mann-Whitney non-
parametric test. Significant differences are given as; *P < 0.05 or **P < 0.01. Comparisons 
over time were evaluated by repeated measures ANOVA. FH, familial 
hypercholesterolemia. CFH, controlFH; Pbo, placebo and g x t, group x time. 
4.3.4.3.2 Ang II infusion 
The results are presented in table 18. Paper V: Neither, peak concentration of thrombin 
generated or endogenous thrombin potential (i.e. total amount of thrombin generated) did 
change during infusion of Ang II. We could observe that the thrombin generation was 
slightly delayed as reflected by increases in the time dependent parameters; lag-time, time 
to peak and time to tail, and this was due to an increase in FH alone during Ang II 
infusion, P time < 0.01, P time < 0.01 and P time < 0.05, respectively. No changes were 
observed in controlFH or placebo. 
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 68 
5 GENERAL DISCUSSION 
5.1 STUDIES IN HYPERTENSION 
5.1.1 Paper I  
The main finding in paper I was that treatment with the ACE inhibitor ramipril, compared 
to placebo, decreased thrombin generation in essential hypertension. TAT complex levels, a 
marker of thrombin generation in vivo, were attenuated after 6 weeks of treatment, and the 
effects were retained after 6 months of therapy. FVII activity levels were unaffected, 
indicating that other mechanisms than reduced availability of FVII were more likely to be 
operating. Fibrinogen levels tended to decrease during ramipril treatment at 6 months (P = 
0.06). These findings are in agreement with findings in overweight hypertensive patients 
treated with perindopril (268).  
Fibrinogen is an acute phase reactant, as well as a marker of the activity in the coagulation 
system. Fibrinogen is an independent risk factor of future CHD (269, 270), and high levels 
of fibrinogen and LDL cholesterol have been reported to be present in plaque formation in 
vessels (271). Furthermore, VSMC migration and proliferation can be stimulated by 
fibrinogen suggesting that fibrinogen might be involved in early plaque formation (271-
273). Fibrinogen also binds to ICAM-1and can stimulate gene expression of this adhesion 
molecule, promoting the adhesion of platelets and leukocytes to ECs (274). Hence, 
fibrinogen mediates inflammation in addition to its central importance in the coagulation 
cascade.   
The attenuated thrombin generation and fibrinogen levels during ramipril treatment could 
be of importance for the reduction of thromboembolic events seen during treatment with 
ramipril in patients at high cardiovascular risk (9). However, the antithrombotic effects of 
ramipril might have been due to the reduction in BP per se. To further assess the 
contribution of BP decrease to the antithrombotic effects we compared ramipril treatment 
with the alpha 1-adrenoceptor blocker doxazosin in paper II. 
5.1.2 Paper II 
5.1.2.1 Coagulation 
Confirming our findings in paper I, plasma levels of TAT complex decreased by ramipril 
therapy in paper II. As TAT complex was unaffected in the doxazosin group, and the 
reductions in BP between the groups were comparable and there was no relation between 
changes in TAT complex and changes in BP by treatment, the anti-thrombin effects of 
ramipril are not likely to be related to reduction in BP.   
Ang II has been reported to up-regulate expression of the key initiator of coagulation, tissue 
factor (11), and tissue factor is elevated in hypertensive patients, as compared with 
normotensive controls (275). Studies in vitro and in vivo have shown that Ang II stimulates 
formation of procoagulant MPs from ECs and mononuclear cells (276, 277), and that 
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ACE inhibition reduces monocyte tissue factor expression and activity in plasma in 
hypertensive patients (12, 278). Our findings of reduced plasma levels of TAT complex 
following treatment with ramipril is in line with a decreased expression and activity of 
tissue factor by ACE inhibition, resulting in an attenuated thrombin generation in plasma. 
This confirms our previous findings (12) and clearly provides one possible mechanism by 
which ACE inhibition may reduce the risk of atherothrombotic complications in high-risk 
cardiovascular patients (279, 280).   
We observed no changes in CAT data over time in the ramipril or the doxazosin treated 
groups. CAT measures thrombin generation potential in plasma ex vivo, while TAT 
complex measures thrombin generation in vivo including effects exerted by the vascular 
endothelium and blood flow (281). In the present study thrombin generation potential in 
plasma ex vivo was unaltered. However, as we added exogenous tissue factor and 
phospholipids to trigger thrombin generation in the plasma samples, the contribution of 
tissue factor exposing MPs in the patient sample cannot be properly evaluated.  Thus, we 
cannot exclude the possibility that the reduced levels of TAT complex in the ramipril 
treated group reflect an attenuated thrombin generation which is, at least partly, due to 
reduced expression of tissue factor on MPs originating from e.g. ECs and/or monocytes. 
To get a better understanding of such mechanisms, one should measure plasma 
concentrations of MPs exposing tissue factor, as well as its origins, which could be the 
focus of future studies.  
It is to be noted that other mechanisms may operate to reduce the levels of thrombin 
generation by ramipril that we observed in papers I and II. Natural inhibitors such as AT, 
the PC system or TFPI may contribute to the attenuated levels of TAT complex observed. 
In conclusion, in papers I and II antihypertensive treatment with ramipril suggest reduced 
thrombin generation beyond the effects on BP reduction alone. Thus, drugs blocking the 
RAAS may reduce atherothrombotic complications beyond their effects to reduce BP. 
Whether these effects are present also with ARB drugs remain, however, to be studied. 
5.1.2.2 Fibrinolysis 
We observed no significant changes in PAI-1 activity by ramipril or doxazosin treatment. 
Levels of t-PA antigen tended to increase during ramipril treatment, while it was decreased 
by doxazosin. ACE inhibitor treatment increase the levels of bradykinin due to a reduced 
degradation (282), which entails anti-ischemic and antihypertensive effects due to 
vasodilatation, and also increased fibrinolysis (283). The tendency to increased t-PA 
antigen concentrations by ramipril might be due to increased levels of bradykinin. 
Hypertension has been associated with hypofibrinolysis with elevated of PAI-1 activity and 
decreased t-PA activity (284-286), and PAI-1 is related with insulin resistance, glucose 
intolerance, hyperinsulinemia and dyslipidemia (287). The alpha 1-adrenoceptor blocker 
doxazosin has been shown to improve insulin resistance, glucose intolerance, 
hyperinsulinemia and to improve the lipid profile (288, 289), features often present in 
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hypertensive patients (290). Therefore alpha 1-adrenoceptor blockers have been associated 
with positive effects on the fibrinolytic system, and it has been suggested that alpha 1-
adrenoceptor blockers preferentially should be used in the treatment of hypertensive 
patients with insulin resistance (291). Our observation with a decrease in t-PA antigen and 
a tendency to decreased PAI-1 activity in the doxazosin treated group would implicate 
beneficial effects by treatment with doxazosin in hypertensive patients regarding 
fibrinolysis. This may be of benefit in the treatment of patients with hypofibrinolysis, such 
as patients with FCHL. 
5.1.2.3 Inflammation 
We measured several markers of inflammation (hsIL-6, IL-6R, IL-8, TNF-α, MCP-1, and 
hsCRP). Antihypertensive treatment overall did not affect hsIL-6, although there were 
directional differences between ramipril (increase) and doxazosin (decrease); and IL-6R did 
note change in either group. The pleiotropic cytokine IL-6 exerts proinflammatory and anti-
inflammatory properties and is produced by various cells in the cardiovascular system 
(292). IL-6 stimulates signalling pathways in the cell when it binds to its receptor, 
membrane-bound IL-6 R, named classic-signalling. Signal-transduction is mediated when 
the IL-6/membrane-bound IL-6R complex associates with the membrane-bound receptor 
gp130, which dimerizes and then initiates intracellular signalling pathways. Membrane-
bound IL-6R is present in few cells in the human body, especially in some leukocytes and 
hepatocytes. In the other pathway, named trans-signalling, circulating IL-6 binds to a 
soluble form of IL-6R, and this complex of IL-6/soluble IL-6R can activate most cells as 
gp130 is expressed uniformly in the human body. The soluble form of gp130 in human 
blood is considered a natural inhibitor of IL-6 trans-signalling, when binding to circulating 
IL-6/soluble IL-6R. The proinflammatory influences of IL-6 are associated with trans-
signalling, whereas regenerative signalling and anti-inflammatory effects have been 
attributed to IL-6 classic-signalling (293). The concentration of soluble IL-6R and soluble 
gp130 in human serum is normally 1000-fold compared to IL-6, and if the increase in IL-6 
is modest, the cytokine will consequently be neutralized (294). In our study the change in 
IL-6 was modest, while soluble IL-6R did not change. Thus, our observed increase in IL-6 
in the ramipril treated group might suggest an increased classic-signalling (i.e. anti-
inflammatory) cytokine action. However, IL-6 most probably acts in a paracrine fashion, 
and IL-6 might reach much higher concentrations in the local inflammatory areas than what 
we are able to measure in peripheral veins. 
IL-8 is a chemotactic cytokine released by macrophages and ECs, attracting neutrophils 
and monocytes to the site of inflamed ECs(295). IL-8 is related with an increased incidence 
of future CHD (296).  In our study we did not see any difference in IL-8 levels due to 
treatment with ramipril or doxazosin. TNF-α is a pleiotropic cytokine primarily released 
by monocytes and macrophages, essential in the initial activation of vascular inflammation, 
and is like IL-6 central in the acute phase reaction. TNF-α plays a fundamental role in 
endothelium dependent vasodilatation (297) and in insulin resistance (298), and is elevated 
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in obese subjects (299). Ang II may be one of the factors that regulate TNF-α (300). We did 
not observe any changes in TNF-α during ramipril or doxazosin treatment. MCP-1 is a 
potent chemotactic factor that regulates migration and infiltration of leukocytes across the 
vascular endothelium, and MCP-1 has been associated with early development of 
atherosclerosis (301). MCP-1 is increased by oxidative stress and by stimulating factors 
such as cytokines and growth factors, and the major source of MCP-1 is monocyte and 
macrophages (302). Ang II can induce oxidative stress and leukocyte adhesion to human 
ECs (303, 304). Similar to our findings with TNF-α, we observed no changes in MCP-1 
levels during treatment with ramipril or doxazosin. Others have found decreased levels of 
MCP-1 during ACE inhibitor treatment in hypertension and in CHD (278, 305), but little 
has been reported on the effect of doxazosin treatment. One study has reported inhibition 
by doxazosin on MCP-1 directed migration of human monocytes (306). CRP is an acute-
phase protein of hepatic origin, regulated by cytokines, mostly by IL-6 and TNF-α (32). In 
consort with the minor effects in IL-6 and TNF-α we observed no changes in hsCRP by 
ramipril or doxazosin. This is in line with findings in studies in hypertension with ACE 
inhibitors or angiotensin receptor blockers (160, 307), while doxazosin has been reported to 
decrease CRP, increase nitric oxide, and to decrease oxidative stress in hypertensive 
patients (308, 309).  
In conclusion, circulating IL-6 may not be a sensitive marker to assess the potential 
influence of RAAS blockade on paracrine effect of IL-6 trans-signalling effects at 
inflammatory sites in human vessels in the clinical setting. Our results with IL-8, TNF-α, 
MCP-1, and hsCRP suggest that otherwise healthy patients with mild-to-moderate 
hypertension represent a population with a low activity of systemic inflammation, and 
detectable effects of antihypertensive treatment may require more advanced atherosclerotic 
disease. 
5.2 STUDIES IN FAMILIAR HYPERLIPIDAEMIA 
5.2.1 Papers III and IV 
5.2.1.1 Characteristics of FCHL 
FCHL exhibited higher IL-6, CRP and leukocyte counts compared to controls, whereas 
TNF-α level were similar in both groups. Hyperinsulinemia may influence the release of 
IL-6 from adipocytes, and the inflammatory mediators IL-6, CRP, fibrinogen and leucocyte 
count are all associated to the metabolic syndrome, without dependence of obesity (32, 310, 
311). Others have calculated insulin resistance by HOMA-IR in FCHL and confirmed that 
patients with FCHL are associated with insulin resistance (167, 312, 313). In visceral 
obesity, adipocyte tissue secretes several inflammatory adipokines, such as CRP, IL-6, 
fibrinogen and angiotensinogen. This indicates the importance of adipocytes in 
inflammatory states, contributing to vasculopathy and cardiovascular risk (314). IL-6, CRP 
and leukocyte count are all associated with increased incidence of CVD (35-37, 315). 
CRP has by itself proatherogenic and proinflammatory properties and CRP may directly 
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induce activation of ECs (316), and increased levels of CRP is closely associated with 
CHD risk factors, especially obesity and deposition of visceral distribution, in individuals 
with or without CHD (317). Hypertriglyceridemia, but not hypercholesterolemia is 
associated with increased leukocyte count (318). The FCHL patients had indeed very high 
concentrations of triglycerides (7.4 ± 5.7 mmol/L), which possibly has an impact of our 
results, as triglyceride levels above 1.7 mmol/L have been reported as an independent risk 
factor for CHD (319). Thus, our present findings prove additional evidence for a low-grade 
chronic inflammation in FCHL, and also suggest that patients with FCHL, to some extent, 
suffer from the metabolic syndrome 
The patients with FCHL exhibited an almost 6-fold higher PAI-1 activity and a 3-fold 
higher t-PA/PAI-1 complex level, when compared to control subjects, in agreement with 
previously reported studies and by us and others (27, 167, 313). PAP complex is a measure 
of the generation of plasmin and a marker for in vivo fibrinolysis, and increasing 
concentrations probably reflects increased t-PA activity (320). We observed higher PAP 
complex concentrations in FCHL compared to controls, which suggest that FCHL 
exhibited increased activities in both the activating and inhibitory proteins.   
F1+2 is a in vivo thrombin generation marker, and may predict CHD (321). In our study 
patients with FCHL and controls had similar concentrations of F1+2 and TAT complexes, 
i.e. no evidence of increased thrombin generation in vivo. This is somewhat unexpected 
since FCHL showed a low-grade inflammatory state, and inflammation may induce 
coagulation through several mechanisms (induced ED, activation of platelets and the 
coagulation cascade through TF, suppression of anticoagulant pathways and impaired 
fibrinolytic activity), and others have reported that FCHL is characterized by impaired 
endothelium reactivity and hypercoagulability (167). One explanation could be that the 
FCHL participants in that study (167) had a high prevalence of CHD, which in most studies 
is associated with high levels of F1+2 and TAT complex (322). In contrast, our patients 
were otherwise healthy, not obese, and were relatively young. 
Thus, patients with FCHL exhibited a low-grade chronic inflammation, and signs of 
impaired fibrinolysis. They also suffered from insulin resistance and showed signs of the 
metabolic syndrome.     
5.2.1.2 Blood pressure effect during Ang II infusion 
The systolic BP response to Ang II was increased in FCHL, as compared to controls, 
indicating that FCHL exhibited increased vascular reactivity. This is possibly a sign of ED 
in patients with FCHL. 
5.2.1.3 Coagulation during Ang II infusion 
In paper III, F1+2 and TAT complex values remained unchanged in FCHL and controls 
during infusion of Ang II. This is in contrast to a previously reported increase in TAT 
complex and a tendency to increased F1+2 during short-time Ang II infusion in healthy 
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males (13). However F1+2 exhibits a diurnal decrease during morning hours (323, 324) but 
the possible effects of diurnal variations of these markers were not taken into account in 
paper III. Our post hoc analyses show that TAT complex actually increased in a similar 
way in controls and FCHL during the ongoing  Ang II infusion (table 17 and figure 
19).This is likely to be due to the short half-life of Ang II (about 15 seconds) (325), and 
TAT complex (5-15 minutes) (326). When the Ang II infusion ceased, the short half-life of 
TAT complex resulted in a decrease in TAT levels 1 h after the end of the infusion. F1+2 
has a longer half-life (90 minutes) (326), which means that the cessation of Ang II infusion 
did not markedly affect the concentration of F1+2 60 minutes later. We did not perform 
placebo infusion experiments in this study, but others have shown that TAT complex has 
no diurnal variation during daytime (327). Taken together, circulating Ang II seems to 
increase thrombin generation. The cause of the increased thrombin generation is unclear. 
Inflammatory stimuli can through several mechanisms prime the coagulation system, and a 
proposed mechanism is cytokine caused TF expression by the cytokines IL-6 (201). During 
Ang II the levels of IL-6 increased. Possibly Ang II may stimulate activation of TF, at least 
in part due to increased concentrations of IL-6. Platelet activation by circulating Ang II (13) 
may have an important contributing role in the generation of thrombin. 
5.2.1.4 Fibrinolysis during Ang II infusion 
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our placebo infusion study. Ang II has been shown to stimulate cultured human coronary 
ECs in a time dependent manner, to release PAI-1 protein and even very low levels of Ang 
II induced PAI-1 protein, which could be detected already after 6 h (331). Others have 
reported that Ang II increased PAI-1 messenger RNA expression in cultured human 
adipocytes after 3 h and PAI-1 protein release after 12 h (332). Hence, it has been argued 
that increased levels of Ang II are closely associated with elevated levels of PAI-1. On the 
contrary, studies by us and others show that PAI-1, is unaffected by Ang II infusion (226, 
227). Ang II may induce PAI-1 release in the long-term setting, but we could not find any 
short-term impact of Ang II on the concentrations of PAI-1.  
PAP complex concentrations remained unchanged during infusion of Ang II in FCHL, 
while these levels increased in controls. PAP complex levels remained unchanged with 
placebo infusion, suggesting no diurnal variation in PAP complex during morning hours. It 
has also been reported that the major plasmin inhibitor alpha-2 antiplasmin lacks diurnal 
variation (330). As PAP complex is a measure of the generation of plasmin and a marker 
for in vivo fibrinolysis, we propose that the increased PAP complex levels seen in the 
controls during stimulation by Ang II us caused by an increase in t-PA activity, in 
accordance with previous findings in vitro and in healthy volunteers (227, 331). The “non-
response” of PAP complex concentrations during infusion of Ang II in FCHL, reflecting 
unchanged t-PA activity, may suggest incapacity of the ECs to release t-PA in response to 
Ang II, compatible with ED in FCHL. Taken together, Ang II seems to increase the 
fibrinolytic capacity by an increased t-PA activity concentration, at least in the short run, 
and argue against the claim that a brief stimulation by Ang II impairs fibrinolysis. Contrary 
to previous claims, we could not observe any short-term impact on PAI-1 activity by Ang II 
stimulation. 
5.2.1.5 Inflammation during Ang II infusion 
Ang II caused a 2- to 3-fold increase in IL-6, similar in FCHL and in healthy controls. This 
is in accordance with findings in rat VSMCs in vitro and in healthy controls showing a 
dose dependent release of IL-6 (106, 333). IL-6 may be produced by a number of cells and 
the origin of IL-6 by Ang II stimulation cannot be determined from our study. 
Unfortunately, we did not measure soluble IL-6R, and therefore it is doubtful to estimate 
the proinflammatory or anti-inflammatory effects due to the increase of IL-6 
concentrations. The possible paracrine increase of IL-6 levels at inflammatory sites is 
generally difficult to measure. The marked increase in IL-6 in our study could suggest that 
IL-6 may have reached even higher levels at local areas in vessels, which may represent a 
local increase of trans-signalling, and a proinflammatory effect. Due to the substantial 
increase in IL-6 levels during Ang II infusion we suggest that Ang II may have 
proinflammatory effects. 
The leukocyte count increased in a similar way in FCHL and controls during infusion of 
Ang II, and this is in line with results reported by others (334). The mechanism for this 
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increase is unknown, but the Ang II stimulated response in leukocyte count supports the 
assumption that Ang II may exert proinflammatory effects.  
TNF-α concentration remained unchanged by the infusion of Ang II, and this extends 
observations reported by others (335). Probably stimulation during longer periods of time 
by Ang II may be necessary to stimulate TNF-α synthesis and release, as indicated by 
animal experiments (336). In any case we can conclude that TNF-α was not the cause for 
the observed increase in IL-6 in our study.    
5.2.2 Paper V 
5.2.2.1 Characteristics of FH 
IL-6, leukocyte count and CRP concentrations remained similar in FH and controls, 
suggesting no convincing signs of systemic inflammation in FH.  
FH and controls had comparable levels of PAI-1 activity. Furthermore, PAP complex 
levels were equal in FH and control subjects. Thus, FH patients exhibit an intact and 
unaffected fibrinolytic system.   
An association between F1+2 levels and total cholesterol and LDL cholesterol levels has 
been reported in hypercholesterolemic patients in advance of atherosclerotic CVD events 
(337). In our study the F1+2 concentrations were not different in FH patients and in 
controls. However using the CAT method, the thrombin generation potential was higher 
in FH compared to controls, in accordance with the assumption that FH is a 
prothrombotic state. We observed higher fibrinogen concentrations in FH compared to 
controls, in agreement with others (338, 339). As data has been presented indicating that 
fibrinogen mediates inflammation beyond its central importance in the coagulation 
cascade, we speculate that the observed high fibrinogen levels in FH subjects imply 
activation of the coagulation system and represent signs of early, silent atherosclerosis.  
In conclusion, FH showed an intact fibrinolysis, while the thrombin generation potential, 
i.e. significantly higher levels of the CAT parameters peak thrombin concentration and 
endogenous thrombin potential, was increased compared to controls. 
5.2.2.2 Blood pressure effects during Ang II infusion 
FH did not show any signs of increased vascular responsiveness to Ang II. 
5.2.2.3 Coagulation during Ang II infusion 
F1+2 levels remained unchanged in FH and controls during Ang II infusion, in spite of the 
elevated IL-6 levels. The absence of the expected diurnal decrease in F1+2 concentrations 
during morning hours, during stimulation by Ang II, may be considered as a relative  
increase in thrombin generation, similar to findings in healthy subjects (13) and in FCHL 
patients (340). Regarding CAT analyses, Ang II did not affect the concentration dependent 
thrombin generation data, peak thrombin concentrations and endogenous thrombin 
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potential. Instead we observed an effect on the time dependent parameters in FH patients, 
i.e. slightly prolonged lag-time, time to peak thrombin concentration, and time to tail. How 
to interpret these results is somewhat unclear. Increased time to peak thrombin has been 
reported in acute coronary syndromes (341, 342), possibly due to increased TFPI plasma 
levels (341). One may speculate that the putative endothelial perturbation in patients with 
FH may cause EC release of TFPI during infusion of Ang II, which binds to TF added in 
the CAT analysis and leads to the delay of thrombin generation. This might be taken to 
suggest that patients with FH exhibit an activation of the anticoagulant system. We 
conclude that Ang II affects thrombin generation in the short run. The increase in 
fibrinogen concentrations were modest during infusion of Ang II, while the most important 
regulator of fibrinogen, IL-6, increased. We did not measure changes in fibrinogen during 
placebo infusion, but others have shown that fibrinogen does not have a diurnal variation 
during morning hours (329). Others have reported that fibrinogen responds to stimulation 
by IL-6 with a long delay of time (266). Thus, the duration of our experiments was 
probably too short to cause a substantial change in fibrinogen levels. 
5.2.2.4 Fibrinolysis during Ang II infusion 
PAI-1 activity decreased during infusion of Ang II, similarly in FH and controls. A similar 
decrease occurred during placebo infusion. Our results thus reflect the diurnal variation in 
PAI-1 activity (330). PAP complex increased similarly in FH and controls during Ang II. 
As alpha-2 antiplasmin lacks diurnal variation (330), and PAP complex did not show any 
diurnal variation in our placebo infusion group, we conclude that the increase in PAP 
complex levels were caused by an increase in t-PA activity, in accordance with our 
previous results (227). Thus, Ang II causes an acute increase in fibrinolysis.  
5.2.2.5 Inflammation during Ang II infusion 
Ang II stimulation caused a marked increase in both IL-6 and leukocyte count, similarly in 
both groups, extending reports in healthy subjects (13, 333, 334) and in accordance with 
our finding in FCHL and healthy control subjects. Although the origin of IL-6 or leukocyte 
count cannot be determined, our results indicate that Ang II may have proinflammatory 
properties.  
Thus, we suggest that patients with FH have an increased thrombin generation, rather than 
alterations in the fibrinolytic activity or in inflammation, and this contributes to the 
increased risk of future CHD and premature death in FH. We also suggest that Ang II in 
FH, in the short run, acts as a proinflammatory, profibrinolytic and a prothrombotic agent. 
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6 CONCLUSIONS 
 Antihypertensive treatment with the ACE inhibitor ramipril reduces thrombin 
generation and tends to lowers fibrinogen concentrations. This effect of ramipril on 
thrombin generation goes beyond the effects on BP reduction alone. Thus, drugs 
blocking the renin-angiotensin-aldosterone system may reduce atherothrombotic 
complications beyond their effects to reduce BP.    
 
 Our observation that doxazosin decreased t-PA antigen and a tended to decrease PAI-1 
activity would implicate beneficial effects by treatment with doxazosin in hypertensive 
patients regarding fibrinolysis. This may be of value in the treatment of patients with 
hypofibrinolysis, such as patients with FCHL.  
 
 Patients with FCHL have signs of an ongoing low-grade systemic inflammation and 
impaired fibrinolysis, while the coagulation system is intact. In contrast, patients with 
FH have an activated coagulation, intact fibrinolysis but no convicing signs of systemic 
inflammation.  
 
 In contrast to FH, patients with FCHL share several charateristics with the metabolic 
syndrome, including high triglyceride and low HDL cholesterol levels, insulin 
resistance and high body mass index. 
 
 In healthy individuals circulating Ang II acts as a proinflammatory agent and may 
increase thrombin generation and fibrinolysis. Since inflammation participates in 
vascular remodelling and atherosclerosis, Ang II may contribute to vascular 
dysfunction in hypertension.     
 
 In patients with FCHL and FH, Ang II acts as a proinflammatory agent and may 
increase thrombin generation. Patients with FCHL appear to be incapable of increasing 
fibrinolysis in response to circulating Ang II, while patients with FH, on the contrary, 
seem to increase their fibrinolysis. 
 
 In contrast to previous claims, we observed no effects of short term circulating Ang II 
on PAI-1 activity in healthy individuals or in patients with familial hyperlipidaemia. 
 
 Thus, blocking the renin-angiotensin-aldosterone system by an ACE inhibitor may 
prevent atherothrombotic complications in hypertensive patients by reducing thrombin 
formation beyond the effects on BP. Different mechanisms may contribute to the 
increased incidence of cardiovascular complications in patients with FCHL and FH. 
ACE inhibitor treatment might be of benefit in patients with FCHLby reducing 
inflammation and insulin resistance, and in patients with FH mainly by reducing 
thrombin generation. 
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7 FUTURE PERSPECTIVES 
Treatment with the ACE inhibitor ramipril reduced thrombin generation beyond the effects 
on BP reduction alone (Paper II). Possibly the reduced levels of TAT complex reflect an 
attenuated thrombin generation which is, at least partly, due to a reduced expression of 
tissue factor on MPs originating from ECs and/or blood cells To get a better understanding 
of such mechanisms, one should measure plasma concentrations of MPs exposing tissue 
factor, as well as its origins. 
FH showed an intact fibrinolysis while the thrombin generation potential, i.e. 
significantly higher levels of the CAT parameters peak thrombin concentration and 
endogenous thrombin potential were increased, as compared to controls (paper V). 
Possibly the increased thrombin generation, measured by TAT complex, in FH may be 
due to an increased expression of tissue factor on MPs originating from ECs and/or blood 
cells. To study the mechanisms involved, it would be worthwhile to examine plasma 
concentrations of MPs exposing tissue factor, as well as its origins. 
ARB also inhibits RAAS, but through a different mechanism compared to ACE inhibitors. 
Blocking AT1R with an ARB will inhibit the negative feed-back on renin with increased 
renin concentrations and subsequently an increase in Ang II, while bradykinin levels are 
unaffected. Thus, ARB treatment may activate AT2R, which mediates effects generally 
opposite to the effects mediated by AT1R. Hence, several different mechanisms are in 
action when using an ARB, compared to the use of an ACE inhibitor. Therefore, it would 
be interesting to study the effects on inflammation and haemostasis in hypertensive patients 
and to compare treatment of an ARB to treatment with doxazosin, i.e. a similar design as in 
paper II, but changing the ACE inhibitor to an ARB. 
Oxidized LDL induces TF expression in ECs and monocytes, and patients with raised LDL 
cholesterol levels exhibit increased TF plasma activity. Statins have been shown to reduce 
TF expression in ECs, monocytes and VSMCs. It would be interesting to examine the 
origin of TF expression in combination therapy with an ACE inhibitor and a statin and to 
compare with statin treatment alone in patients with high concentrations of cholesterol, 
such as FH. 
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8 SVENSK SAMMANFATTNING 
Åderförkalkning är multifaktoriell och endoteldysfunktion (begynnande funktionsskada i 
kärlväggen) anses föregå åderförkalkning. Angiotensin (Ang) II, den huvudsakliga 
effektorn av renin-angiotensin-aldosteronsystemet (RAAS), är inblandad i hypertoni och 
har visat sig bidra till åderförkalkning. Läkemedlet ”angiotensin converting enzyme” 
(ACE) hämmare minskar bildningen av Ang II. 
Två vanliga blodfettsrubbningar; familjär kombinerad hyperlipidemi (FCHL) och familjär 
hyperkolesterolemi (FH), har båda identifierats som riskfaktorer för hjärt-kärlsjukdomar 
och för tidig död. FCHL har en annan fenotyp (observerbara egenskaper) jämfört med FH, 
men båda associeras med endoteldysfunktion och en subklinisk åderförkalkning. Vi 
spekulerade i att patienter med hypertoni samt blodfettsrubbningarna FCHL och FH var 
mer känsliga för de potentiella proinflammatoriska och prokoagulatoriska effekterna av 
Ang II jämfört med friska individer. Vi undersökte därför hur RAAS påverkar 
inflammation och koagulation hos friska kontroller samt hos individer med hypertoni och 
FCHL respektive FH. 
I delarbete I undersökt vi effekten av behandling med ACE hämmaren ramipril avseende 
koagulation hos patienter med mild-till-måttlig hypertoni. Vi observerade att ramipril 
dämpade bildningen av trombin (förorsakar blodkoagulering) hos individer med essentiell 
(utan känd orsak) hypertoni. Vi såg också en tendens till minskade nivåer av fibrinogen. 
I delarbete II ville vi klargöra effekten av blodtryckssänkande behandling i sig. Därför 
undersökt vi effekterna av 3 månaders behandling med ramipril jämfört med doxazosin, 
som är en blodtrycksmedicin utan någon påverkan på RAAS, avseende inflammation och 
koagulation hos patienter med mild-till-måttlig hypertoni. Vi fann att blodtryckssänkande 
behandling i sig hade en begränsad effekt på systemisk inflammation. Behandling med 
ramipril, men inte doxazosin, tycktes minska bildningen av trombin. Detta utökade våra 
tidigare resultat från delarbete I genom att vi här visade att behandling med ramipril 
minskade trombin bildningen, utöver de blodtryckssänkande effekterna. Läkemedel som 
blockerar RAAS kan därmed minska aterotrombotiska komplikationer utöver de 
blodtryckssänkande effekterna. Vi observerade också fördelaktiga effekter på fibrinolysen 
(system som löser upp blodkoagler), som skulle unna tala för positiva effekter av 
behandling med doxazosin hos hypertensiva patienter avseende fibrinolys. Detta kan vara 
till nytta vid behandling av patienter med nedsatt fibrinolys, såsom patienter med FCHL.  
I delarbete III undersökte vi hur en intravenös infusion av Ang II under 3 timmar 
påverkade inflammation och koagulation hos patienter med FCHL och friska 
kontrollpersoner. I Delarbete IV beskrev vi patienterna med FCHL i delarbete III, 
ytterligare med avseende på deras insulinresistens och fibrinolys. Vi genomförde också 
placebo experiment för att göra det möjligt att bedöma påverkan av de dagliga 
variationerna och kontrollera stabiliteten i vår experimentella design. Vi fann att FCHL 
hade ett förhöjt systoliskt blodtryckssvar under infusionen av Ang II jämfört med 
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kontroller, vilket skulle kunna tala för en ökad endoteldysfunktion hos FCHL. Patienter 
med FCHL uppvisade en låggradig kronisk inflammation och en nedsatt fibrinolys, medan 
koagulationssystemet däremot föreföll vara intakt. FCHL hade flera kännetecken för det 
metabola syndromet; höga triglycerid och låga HDL kolesterol nivåer, insulinresistens och 
ett högt kroppsmasseindex. Infusion av Ang II ökade systemisk inflammation på ett 
liknande sätt hos FCHL och kontroller. Ang II medförde inte någon påverkan på bildandet 
av trombin, vare sig hos FCHL eller hos kontrollerna. Ang II påverkade inte fibrinolysen 
hos FCHL, medan fibrinolysen däremot ökade hos de friska kontrollerna. De olika svaren 
för Ang II stimuleringen berodde förmodligen på att patienter med FCHL är oförmögna att 
öka sin fibrinolys som svar på Ang II. Vi kunde inte observera några kortsiktiga effekter på 
PAI-1-aktiviteten, varken hos FCHL eller hos kontrollerna. Våra fynd talar för att patienter 
med FCHL har en låggradig kronisk inflammation, en nedsatt fibrinolytisk kapacitet och 
flera kännetecken för det metabola syndromet, som alla bidrar till den ökade risken för 
hjärt-kärlsjukdomar och för tidig död hos FCHL. Vi föreslog också att Ang II verkar 
proinflammatoriskt och förorsakar en ökad fibrinolys, utan någon inverkan på trombin 
bildningen. Effekterna av de dagliga variationerna av våra markörer för koagulationen togs 
inte i beaktande i delarbete III. Om effekterna av Ang II däremot analyseras under den 
faktiska infusionstiden, visade nya data istället att bildandet av trombin istället ökade hos 
både FCHL och kontrollerna. Vår nya slutsats blev därför istället att Ang II verkar 
protrombotiskt. 
I delarbete V undersökte vi hur en intravenös infusion av Ang II under 3 timmar 
påverkade inflammation och koagulation hos patienter med FH och friska kontroller. Vi 
genomförde också placebo experiment för att göra det möjligt att bedöma påverkan av de 
dagliga variationerna och kontrollera stabiliteten i vår experimentella design. Vi fann att 
patienter med FH hade högre systoliskt blodtryck än kontrollerna, medan blodtryckssvaren 
var lika hos FH och kontrollerna. FH uppvisade en intakt fibrinolys, men en ökad potential 
att bilda trombin jämfört med kontrollerna. FH hade inte några övertygande tecken på en 
pågående låggradig inflammation. Infusion av Ang II orsakade en ökning i inflammation, 
fibrinolys och troligen bildandet av trombin, på samma sätt hos både FH och kontrollerna. 
Under Ang II infusionen visade FH tecken på ett aktiverat antikoagulerande system. Vi 
föreslog att patienter med FH har ett aktiverat koagulationssystem i stället för en förändrad 
fibrinolys eller inflammation, vilket kan bidra till den ökade risken för hjärt-kärlsjukdomar 
och för tidig död hos FH. 
Vår slutsats blev att blockering av RAAS genom att använda en ACE hämmare kan 
förhindra aterotrombotiska komplikationer hos patienter med hypertoni, utöver effekterna 
av blodtryckssänkningen framför allt genom att minska bildandet av trombin. Olika 
mekanismer kan bidra till ökningen av kardiovaskulära komplikationer hos patienter med 
FCHL och FH. Hos patienter med FCHL kan en effekt av ACE hämning vara att dämpa 
inflammation, i kombination med deras kända positiva inverkan på insulinresistens, och 
hos patienter med FH förefaller den huvudsakliga effekten vara att minska bildningen av 
trombin. 
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